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INTRODUCTION 
1.1 Acute myeloid leukemia 
Acute myeloid leukemia is a malignant clonal proliferation of immature 
hematopoietic cells. Leukemic blasts may express abilities for maturation to 
a variable degree, which leads to morphological heterogeneity. Generally the 
transformed leukemic stem cell is committed to the granulocytic lineage. 
Sometimes a predominance of blast cells from the erythroid or megakaryo-
cytic lineage may be observed. The leukemic transformation may occur at 
the level of a pluripotent or a less primitive hematopoietic cell. (1,2,3) This 
is apparent from the observation of clonal markers, e.g. unique cytogenetic 
abnormalities in single versus several blood cell lineages. (4) 
1.2 Leukemogenesis 
It is generally accepted that leukemia is the result of a multistep process. 
(5,6) According to this idea, the leukemia-initiating cells initially contain a 
single genetic lesion resulting in none or only slight differences in prolifera-
tion and cell survival as compared to their normal counterparts. Additional 
genetic lesions may result in full leukemic transformation. The search for 
the targets of oncogenic events has elucidated various mechanisms that lead 
to leukemia. Genetic lesions may result in the activation of genes that con-
tribute to leukemogenesis (oncogenes) or loss of the activity of genes that 
prevent tumor growth (tumor suppressor genes). (7) The genes that are 
involved in leukemia affect specific cellular regulatory mechanisms: growth 
factor receptor function, e.g. G-CSF (8,9,10,11), signal transduction (e.g. 
the ras family (12)), transcription (e.g. myc (13)) , differentiation (e.g. 
RARJPML (14)) or programmed cell death (e.g. bcl-2 (15) pS3 (16,17)) 
Proliferation of AML cells is controlled by hematopoietic growth factors 
(HGF). In vitro leukemic cells from some cases exhibit spontaneous prolif-
erative activity. This may be caused by the autocrine production of HGF or 
by constitutional activation of metabolic pathways, that are normally acti-
vated only when a growth factor signals via its receptor. (18) In normal 
hematopoiesis the proliferation of blood cells induced by HGF is accompa-
nied by maturation and loss of clonogenic potential. 
1.3 Epidemiology 
The incidence of AML in the Netherlands is 2.5 cases per 100,000 indivi-
duals per year. (19) The incidence increases with age, e.g. from less than 1 
per 100,000 persons per year under the age of 20 to more than 10 per 
100,000 persons over the age of 70. (20) 
Some environmental factors have been consistently linked to this disease: 
radiation exposure (21,22,23), alkylating agents (24), chronic benzene 
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exposure (25), and cigarette smoking. (26) Hereditary conditions may carry 
an increased risk of AML: e.g. Down's syndrome, Bloom's syndrome, 
Fanconi's anemia. (27,28,29) Infrequently families with an unexplained 
high risk of AML have been described. (30) Taken together these categories 
represent a minority of all primary AML patients. Some hematological dis-
eases are associated with a high risk of transformation to (secondary) acute 
myeloid leukemia. The risk is especially high in chronic myeloid leukemia 
(75%) and myelodysplastic syndromes (50%), and less so (incidence 10% 
or less) in polycythemia vera, agnogenic myeloid metaplasia and paroxy-
smal nocturnal hemoglobinuria. In these diseases an additionalleukemoge-
nic event is assumed to determine the transformation of the preexistent 
hematological disease towards acute leukemia. 
1.4 Classification of AML 
The heterogeneity of AML has resulted in a classification of the disease. The 
first efforts to define subgroups of AML were based on a combination of 
morphology and cytochemistry. The French-American-British (FAB) 
Classification is still mainly based on these parameters. (31) The use of this 
system has allowed the identification of typical morphological variants of 
AML. Interestingly, certain morphological variants have now been linked to 
a specific cytogenetic abnormality with a characteristic immunophenotype. 
Acute promyelocytic leukemia (FAB M3) is generally characterized by a 
t(15;17) translocation involving the PML gene on chromosome 15 and the 
retinoic acid receptor- (RAR-) gene on chromosome 17. In this subtype of 
AML all-trans retinoic acid (ATRA) may induce maturation of the AML 
cells in vitro and in vivo. (32,33,34) AML M2 is associated with a translo-
cation t(8;21) involving the AML 1 gene on chromosome 21 and the ETO 
gene on chromosome 8. It occurs in ±15% of de novo AML cases. In these 
leukemias the exposure of the leukemic blasts to G-CSF or IL-5 in serum 
free culture results in morphological maturation towards neutrophils and 
eosinophils, respectively. (35) Acute myelomonocytic leukemia with eosi-
nophilia (AML M4eo) has also been associated with a chromosomal aber-
ration: inversion 16, which gives rise to a new CBF~ IMYH11 fusion trans-
cript. (36) The identification of the latter three classes of AML with a rela-
tively favourable prognosis mark the beginning of a trend to ultimately clas-
sify AML by the DNA-defect. Ideally this shoud lead to distinction of bio-
logical subgroups of leukemias with predictable clinicopathological charac-
teristics and specific lesions that may serve as targets for the design of novel 
therapeutic strategies. 
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1.5 Clinical presentation and treatment of AML 
The accumulation of leukemic blasts in the bone marrow of the patient 
results in interference with normal stem cell proliferation and differentia-
tion. The resulting anemia, leukocytopenia and thrombocytopenia general-
ly explain the symptoms of the patients. Specific problems may result from 
leukemic infiltration (e.g. gums, central nervous system), hyperleukocytosis 
or meta bolic dysregula tion. 
The purpose of AML therapy is to eradicate all malignant cells. Most treat-
ment protocols start with remission induction efforts with a combination of 
cytostatic drugs (generally an anthracyclin and cytarabin). These protocols 
may also include consolidation therapy at varying intensities, depending on 
the subtype of AML and the condition and age of the patient. Treatment-
related toxicity and resistant disease (primary refractory AML or relapse) 
interfere with achievement of long term survival in a majority of patients. 
Long term survival, probably cure is achieved today in 20-40% of patients 
in major studies. (37-53) 
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2 STEM CELLS 
2.1 Normal hematopoietic stem cells 
All mature blood cells develop from a pool of stem cells. These stem cells 
differentiate into progenitor cells which proliferate and mature into blood 
cells of the individual lineages. Although large numbers of relatively short-
lived blood cells are produced every day, hematopoietic stem cells are rare. 
They are functionally defined by their extensive self-renewal capacity and 
the ability to contribute to blood cell formation of multiple lineages for pro-
longed periods of time. The parameter of choice to measure the abilities of 
hematopoietic cell subsets is long-term in vivo repopulation of the hemato-
poietic system. It has been estimated that the frequency of the murine stem 
cell is in the order of 1 or 2 per 100,000 bone marrow cells. (54) 
Characterization of stem cells has required the development of purification 
strategies for normal stem cells and a number of assays that allow te char-
acterization of a defined subset of hematopoietic cells. 
2.2 Concept of AML stem cells 
The concept of tumor stem cells postulates that some cells in a tumor have 
the capacity to maintain long-term growth of the tumor. (55) The progeny 
that is derived from these malignant stem cells lacks these abilities for self-
renewal. Following maturation hematopoietic cells normally become non-
dividing. In acute myeloid leukemia there is a maturation arrest of the 
malignant cells which results in an accumulation of immature blasts. In the 
studies of Lotem and Sachs a mouse leukemia clone was induced to morp-
hologicalmaturation in vitro by a preparation containing several cytokines. 
Morphological maturation was associated with loss of the potential to 
transfer leukemia in vivo. (56) When these experiments were repeated with 
a related leukemic cell clone that was maturation incompetent, survival was 
not prolonged upon cytokine stimulation, suggesting that maturation induc-
tion of the leukemic clone was responsible for the therapeutic effect of the 
cytokines. (57) The progression of the AML cells along the maturation 
route may have resulted in the loss of clonogenic potential. Thus the use of 
cytokines may indeed induce maturation in leukemic cells with long-term 
potential and the activation of normal differentiation pathways may be the-
rapeutic in AML. In man all-trans retinoic acid (ATRA) stimulates cellular 
differentiation in AML M3, resulting in complete remission. Study of the 
characteristics and functional abilities of AML cells with long-term abilities 
may shed light on pathophysiologic mechanisms of therapeutic failure or 
success. 
3 ASSAYS FOR NORMAL HEMATOPOIETIC 
PROGENITOR CELLS 
3.1 Colony forming cells 
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The establishment of in vitro assays allowed studies of hematopoietic proge-
nitor cells and their regulation. (58,59) In vitro these progenitor cells may 
be seeded in a semisolid matrix (e.g. agar, methylcellulose) to form a proge-
ny of colonies of cells. Colony assays have been developed for several subs-
ets of progenitor cells.In such an assay a human or murine multipotential 
progenitor cells common to granulocytes, erythrocytes, monocytes, and 
megakaryocytes (CFU-GEMM) has been defined. (60,61,62) Committed 
progenitor cells of a single lineage may be assessed in the following assays: 
erythroid burst forming units (BFU-E), erythroid colony-forming units 
(CFU-E), granulocyte colony forming units (CFU-G), monocyte colony for-
ming units (CFU-M), granulocyte/monocyte colony forming units (CFU-
GM) or megakaryocyte colony forming units (CFU-Mega). (63-67) The 
CFU-Blast is a subset of in vitro colony-forming cells with the capabilities 
for self-renewal and production of progeny of several lineages, and in part 
defined by stroma adherency. (67) A cell producing very large colonies 
(>0.5mm in diametel; containing at least 50,000 cells) and strictly depen-
dent on a combination of hematopoietic growth factors has been described 
as high proliferative potential colony-forming cell (HPP-CFC). (68,69,70) 
The HPP-CFC has later been divided into several subtypes. These subtypes 
respond to different (combinations of) growth factors and have been ter-
med in order of increasing maturity: Pro-HPP-CFC-1, HPP-CFC-1, HPP-
CFC-2, HPP-CFC-3 and the low proliferative potential colony-forming cell 
(LPP-CFC). However, results of in vivo transplantations could not be pre-
dicted using the HPP-CFC assay.(71) In the murine system a macroscopic 
spleen colony test was among the first assays to be developed for the analy-
sis of hematopoietic precursor cells. (72) Spleen nodules, representing colo-
nies of hematopoietic cells, on day 7 (colony forming unit-spleen (CFU-S) 
day 7) or 12 (CFU-S day 12) after transplantation were shown to be repre-
sentative of cells with the ability to initiate at leat short term repopulation 
of the mouse bone marrow. These cells are in the same range of maturity as 
CFU-Blast or HPP-CFC. Howevel; it has subsequently been shown (e.g. 
using exposure to 5-FU or cell sorting) that the large majority of colony for-
ming cells can be separated from cells with long-term abilities. 
(73,74,75,76) This has led to reappraisal consistent with the notion that in 
vitro colony forming cells in normal bone marrrow mainly represent cells 
with short term, transient in vivo repopulating ability. 
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3.2 Long-term cnlture of human hematopoietic cells 
To detect cells with long-term abilities long-term in vitro stromal cell cultu-
re systems were developed. Hematopoietic cells in the bone marrow are 
sustained by a complex network of other cells. For instance, erythroid 
islands in the marrow consist of a central macrophage surrounded by 
erythroblasts. (77) When clumps of murine marrow are cultured in vitro, a 
confluent stromal layer will develop, and hematopoiesis may be maintained 
for many weeks. Dexter et al. designed culture conditions that allowed the 
development and maintenance of a hemopoietic microenvironment in vitro. 
(78) These cultures sustain a network of multilayered stromal cells, inclu-
ding adipocytes, fibroblastic cells, barrier cells, macro phages, endothelial 
cells and extracellular matrix. (79,80,81) Primitive hematopoietic cells are 
localized beneath or in the stromal layer. On examination with a phase-con-
trast microscope they are phase-dark, in contrast to cells situated above the 
stromal layer which are phase-bright. (82) Cells with the ability to initiate 
long-term growth in vitro are often described as long-term culture initiating 
cells (LTC-IC). Colonies of primitive cells consist of flattened polygonal 
cells. Such primitive clones of at least 5 cells are termed cobblestone areas 
(CA). Upon proliferation and maturation the progeny of these primitive 
cells moves towards the surface of the stromal layer and may be released 
into the medium. (83) The interactions with the components of the stromal 
layer appear complex and may involve the production of hematopoietic 
growth factors and other cytokines. In addition, the contact between the 
hematopoietic cell and the stromal layer may in part regulate hematopoie-
tic cell function, although it has recently been shown with the use of a trans-
well system that direct contact between stroma and hematopoietic cell is not 
required for long-term culture. (84,85) 
3.3 The cobblestone area forming cell assay 
Ploemacher et al. (86) developed a quantitative assay that enumerates the 
numbers of a series of primitive hematopoietic cell subsets in vitro. In this 
assay, stroma is grown in a 96-wells plate. This stromal layer is seeded with 
hematopoietic cells, at limiting dilution. Between 5 days to 9 weeks after 
seeding the wells may be examined for cobblestone areas, using a phase-
contrast microscope. The frequency of the cobblestone area forming cells 
(CAFC) in a given sample is calculated with the use of Poisson statistics, 
based on the proportion of negative wells. It has been shown that the time 
of appearance of a CA after seeding is related to the primitiveness of the 
CAFe. In murine hematopoiesis it was demonstrated that the numbers of 
day 28-35 CAFC of a graft predicted long-term repopulating ability, whe-
reas earlier appearing CAFC were associated with transient repopulating 
ability. (73,86-89) For investigation of human hematopoiesis the murine 
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FMBD-1 cell has been used as a stromal layer. Unstimulated FMBD-1 cells 
express m-RNA for many cytokines e.g. TGF-1~, M-CSF, IL-6 and SCE To 
stimulate growth of the human cells the medium contains many compo-
nents: e.g. IL-3, G-CSF, fetal calf serum (12.5%), horse serum (12.5%) and 
hydrocortisone. It was shown that immature human hematopoietic cells 
with long-term abilities in this assay are characterized as CD34 positive, 5-
fluorouracil resistant, HLA-DRlow, Rhodamine-123dull, and predominant-
ly produce CA at 5-8 weeks following seeding. Hematopoietic cells initia-
ting CA at earlier intervals after the onset of culture were highly sensitive 
to 5-FU, and expressed Rhodamine123 and HLA-DR at varying intensities. 
(73) 
4 ASSAYS FOR AML PROGENITOR CELLS 
4.1 C\onogenic cells in AML 
AML colony forming cells (CFU-AML) may express various phenotypes 
and display considerable heterogeneity among patients. (90,91,92) 
Generally CFU-AML express more immature immunophenotypes as com-
pared to the unseparated AML cell population. This is e.g. apparent from 
the profiles of expression of CD34, CD38, CDw65 and CD15. Cellular dif-
ferentiation of CFU-AML in vitro can be induced. (93,94,95,96) CFU-AML 
recovered from methylcellulose cultures may be replated and some CFU-
AML may produce secondary colonies. (93) The capacities for (limited) dif-
ferentiation and self renewal are consistent with the identity of CFU-AML 
as progenitor cells. As became evident from thymidine suicide studies CFU-
AML are an actively proliferating cell population. (97) 
4.2 Immunodeficient mouse models for human AML 
4.2.1 SCID mice 
In 1983 Bosma reported the discovery of a mouse with severe combined 
immunodeficiency (SCID) in a CB17IIcr inbred strain. (98) The defect was 
shown to be the result of a new recessive mutation, mapping to mouse chro-
mosome 16 near the A-light chain locus. (99) The involved gene has not yet 
been cloned. The phenotype of the SCID mouse consists of many abnorma-
lities. Band T cells are nearly absent. The minimal numbers of Band T cell 
progenitors show a normal rearrangement of the immunoglobulin Jl-gene or 
the T cell receptor ~-chain. SCID mice are prone to develop thymomas. 
There is a striking defect in the repair of double-strand DNA-breaks, ren-
dering the mice extraordinarily sensitive to irradiation. (100) It has been 
suggested that the SCID gene defines a doublestrand DNA break repair acti-
vity that is also required for efficient joining of V(D)] coding ends of the B 
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and T cell receptor. (101) NK cells are present, and may induce graft rejec-
tion. (102,103) Granulocytic, erythroid and megakaryocytic cell differen-
tiation and proliferation appear to be normal. (104) 
4.2.2 SCID mice support long term growth of normal human hemato-
pOIeSIS 
The question whether human hematopoiesis can be established in immuno-
deficient mice has been the subject of active research. The group of John 
Dick showed that SCID mice, that had been conditioned with total body 
irradiation, accept an intravenous graft of human bone marrow. After one 
month 0.5-5% of human hematopoietic cells can be demonstrated in the 
bone marrow of the SCID mouse. Additional treatment with human cyto-
kines (PIXY, a GM-CSFIIL-3 fusion peptide, and stem cell factor) results in 
much higher levels of human cells. Myeloid, erythroid and B cell lineages 
and progenitor cells (CFU-GM, CFU-GEMM) were detected. (105) It has 
been shown that the immunophenotype of the human hematopoietic cell 
engrafting immunodeficient mice is CD34+ICD38-. Engraftment may be 
achieved with as few as 100 cells. In contrast, high numbers of CD34 nega-
tive cells failed to proliferate in these mice. (106) Cells with the ability to 
initiate long-term culture may expand in numbers after transplantation in 
immunodeficient mice. (107) These data indicate that the cell engrafting the 
bone marrow of immunodeficient mice is a primitive hematopoietic cell 
that may maintain hematopoieisis of several blood lineages for at least a few 
months. 
4.2.3. SCID mouse model for AML 
Human AML cells may produce solid tumors when inoculated subcutane-
ously into mice that had been previously immunosuppressed by thymecto-
my and total body irradiation. Such AML tumors grow to a maximum size 
and then regress. At the time of regression the AML cells often show morp-
hological signs of maturation. Sporadically a tumor may be maintained or 
even be retransplanted into a secondary recipient. Dissemination of leuke-
mia in the recipient has not been observed. (108,109) The finding that nor-
mal human hematopoiesis may be sustained in immunodeficient mice for 
several months suggested the possibility of similar establishment of human 
AML in these animals. Howevel; initial experiments with the purpose to 
engraft primary AML in immunodeficient mice failed. Experimental condi-
tions of transplantation of AML into scm mice were the subject of subse-
quent study. (110-118) Pretransplant conditioning, graft size, route of trans-
plantation and HGF support have been shown to influence engraftment and 
subsequent proliferation. Recipients have been prepared for transplanta-
tion with TEl or chemotherapeutic agents. Additional conditioning with 
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asialoGMl antisera, with the purpose to eliminate mouse NK cells, resulted 
in some improvement. (119) Diverse routes of administration of the cells 
have been employed, i.e., subcutaneous, intraperitoneal, intravenous routes 
and injections into fragments of human fetal bone. Engraftment ensued 
following any of these routes, but the optimal way of administration remai-
ned questionable. In the first series of experiments in which reproducible 
growth of human AML in SCID mice was accomplished human hemato-
poietic growth factors (hHGF) were administered as support following 
transplantation. It was shown that hHGF (the investigators used a construct 
of interleukin 3 and granulocyte macrophage colony-stimulating factor 
(PIXY) and stem cell factor) enhanced the outgrowth of AML, although en-
graftment in the absence of hHGF was also seen. (115) A variant of the 
SCID mouse model is the SCID-Im mouse. This model was developed by 
implanting human fetal bone fragments into SCID mice. After injection into 
such bone fragments human hematopoietic cells proliferate in a human 
microenvironment. Multilineage hematopoietic activity is maintained in 
these structures, without exogenous growth factor treatment. (120) In this 
system primary AML could be maintained, allowing retransplantation into 
secondary recipients. (121) More recently a new mouse strain has gained 
interest as a recipient for human hematopoietic cells: the non-obese diabe-
tic (NOD)/SCID mouse. In addition to the SCID defect, this mouse has a 
deficiency of NK cells and a macrophage maturation defect. 
Transplantation experiments of human hematopoietic cells show more 
reproducible engraftment and higher levels of engrafted human hemato-
poietic cells. (122,123) This particular mouse strain will be used more fre-
quently in the foreseeable future. 
5. Introduction to the experimental work 
The experimental work of this thesis consists of two parts. The first part 
relates to exploration of conditions to facilitate engraftment of primary 
human AML in ScrD mice. In Chapter 2 the role of total body irradiation, 
the transplantation route and hematopoietic growth factor support with 
interleukin-3 are investigated. Chapter 3 describes experiments to reduce 
the graft size required for engraftment of human AML cells in the SCID 
mouse bone marrow. Despite the fact that SCID mice are nearly devoid of 
T and B cells there is a substantial residual graft resistance that needs to be 
overcome, which may be mediated by macrophages or NK cells. The effect 
of macrophage depletion of the recipient on the required graft size is inves-
tigated. 
The second part describes experiments aimed at a characterization of leu-
kemic stem cells. Investigation of long-term growth abilities of AML cell 
subsets was performed using two independent assays for long-term growth: 
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the CAFC assay and SCID mouse transplantations. Normal bone marrow 
cells with long-term abilities express the immunological cell surface marker 
CD34. In Chapter 4 the relation between growth characteristics and CD34 
expression of MIL cell subsets is investigated. In view of the heterogenei-
ty of AML it is difficult to identify a common denominator of primitive leu-
kemic cells. We hypothesized that most leukemic stem cells, similar to nor-
mal stem cells, might be more primitive than colony forming cells and be 
out of cell cycle. Experiments to test this hypothesis are presented in 
Cha pteI' 5. Chapter 6 is concerned with the investigation of a possible new 
therapeutic agent, a potent growth factor-toxin conjugate. We asked the 
question as to whether primitive AML cells would be killed by the hemato-
poietic growth factor (GM-CSF) coupled to a Diphteria toxin. 
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ABSTRACT 
Transplantation of human AML into severe combined immunodeficient 
(SCID) mice provides a useful experimental model but graft failure has been 
reported. \Ve investigated the influence of a number of factors on the out-
growth of AML in the SCID mouse bone marrow (BM). The transplanta-
tion mute and the dose of total body irradiation (TBI) were examined using 
the cell line HL-60 as a model for AML. The role of graft size and recom-
binant human IL-3 (IL-3) were investigated with patient samples of AML 
cells. 
Intravenous transplantation was demonstrated to be superior to intraperi-
toneal transplantation. Pretransplant conditioning resulted in a dose depen-
dent increase of AML growth in the SCID mouse. Cell dose titrations ran-
ging from 3xl0'-3.6xl05 AML cells iv per mouse revealed a minimum of 
1.1xl06 to be required for repmducible engraftment. Earlier and more 
extensive infiltration by human AML cells was seen following injection of 
greater cell numbers. 
IL-3 given posttransplantation to SCID mouse recipients, promoted AML 
growth in three cases, whereas a fourth AML cell specimen also grew wit-
hout support of IL-3. In vitro growth factor responsiveness of AML cells to 
IL-3 did not predict IL-3 dependence of AML growth in vivo. 
INTRODUCTION 
Human acute myeloid leukemia (AML) transplanted into severe combined 
immunodeficient (SCID) mice allows for the study of growth and interven-
tions of gmwth of human AML in an in vivo model. Howevel; mainly nnex-
plained graft failures have been observed. The experimental conditions of 
transplantation of AML into SCID mice have varied greatly (1-9). Pretrans-
plant conditioning, graft size, mute of transplantation and human hemopo-
ietic growth factor (hHGF) support might influence engraftment and subse-
quent pmliferation. Conditioning with total body irradiation (TEl) has been 
used in doses ranging from 2 Gy (6,7) to 4 Gy (1,2,4). Recipients have also 
been prepared for transplantation of xenogeneic hemopoietic cell grafts 
with chemotherapeutic agents (8,9). Diverse routes of administration of the 
cells have been employed, i.e., subcutaneous, intraperitoneal (ip), intrave-
nous (iv) routes and injections into fragments of human fetal bone (1-9). En-
graftment ensued following any of these routes, but the optimal way of 
.administration remains unknown. Dose titrations of AML cell numbers 
grafted have been examined, but repopulation has been evaluated after one 
month only (2). The support with hHGFs following transplantation may 
enhance the outgrowth of AML (2), although engraftment in the absence of 
27 
hHGF,s appears possible (1,3,6,8). Recombinant human interleukin-3 (IL-
3) induces leukemic colonies in vitro and activates DNA synthesis in 80% 
of leukemic cell samples obtained from patients with AML (10). We inves-
tigated the conditions mentioned above to establish their influence on en-
graftment and proliferation of human AML in scm mice. 
MATERIALS AND METHODS 
Cell suspensions and culture conditiolls 
Bone marrow (BM) and peripheral blood (PB) samples were obtained follo-
wing appropriate informed consent from four unselected patients presenting 
with AML diagnosed according to the criteria of the French-American-
British Committee (FAB)(l1). Patient A and B were diagnosed as AML Ml 
and had normal cytogenetics, patient C was diagnosed as AML MS and had 
normal cytogenetics and finally patient D suffered from AML M4 and com-
plex cytogenetic abnormalities were identified in the AML cells (43 XY, 
2q+, -4, -7, 10q-, -17). Mononuclear cells were isolated by Isopaque-Ficoll 
centrifugation (1.077 g/cm'; Nycomed, Oslo, Norway). Subsequently E-
rosette forming cells were depleted. The cells were cryopreserved in 10 % 
dimethylsulfoxide (BDH, Poole, UK), 20% inactivated fetal calf serum 
(FCS) and Iscove's modified DulbecCO's medium (IMDM). After thawing by 
stepwise dilution (12), viability assessed by trypan blue staining was always 
> 90%. To determine autonomous proliferation of AML cells the uptake of 
tritiated thymidine by leukemic cells in serum-free and cytokine-free cul-
tures was measured. Autonomous growth was defined as mean tritium thy-
midine uptake of unstimulated cultures> 7.Sxl0'dpm and expressed as de-
cayes per minute divided by 100 as described (13). For assessing IL-3 res-
ponsiveness the uptake of tritiated thymidine in serum-free culture in the 
presence of Sng/ml of IL-3 was measured and compared to the values of cul-
tures without IL-3. A positive IL-3 response was defined as a significantly 
greater tritium thymidine uptake in the presence of rh-IL-3 than in unsti-
mulated control cultures (14). 
HL-60 cells were obtained from suspension cultures in IMDM medium and 
10% FCS at a density of maximally 2 x 10' cellslmL. M-07e cells were cul-
tured similarly using RPMI 1640 medium (Gibco, Paisley, Scotland, UK) 
supplemented with Sng/mL IL-3. 
Mice alld transplantation of AML 
Female specific pathogen free CB17 scid/scid mice were obtained from 
Harlan CPB, Austerlitz, The Netherlands. They were housed under patho-
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gen free conditions in a laminar air flow unit and supplied with sterile food 
and acidified drinking water containing 100mg/L ciprofloxacine (Bayer AG, 
Leverkusen, Germany), Before transplantation the mouse plasma Ig level 
was determined in an ELISA using a sheep anti-mouse Ig specific for mouse 
IgG and IgM (Boehringer Mannheim Biochemica, Penzberg, Germany), 
Only mice with Ig plasma levels <40pg/ml were used for transplantation, 
Transplantation was performed at the age of 6-8 weeks, Total body irradi-
ation was delivered by a J37Cs source adapted for the irradiation of mice, 
Leukemic cells suspended in 300pl Hanks, balanced salt solution (HBSS) 
were injected intravenously (iv) into the lateral tail vein or intra peritoneally 
(ip) on the day after TBL 
Human hematopoietic growth factor supply 
Recombinant human IL-3 (IL-3), Escherichia coli derived, was obtained 
from Sandoz Pharmaceutical Company, (Basel, Switzerland) and was admi-
nistered ip in 300pL (calcium and magnesium free) HBSS and 0,1 % bovine 
serum albumin, As an alternative method of IL-3 supply in vivo scm mice 
received 10' cells from an IL-3 producing cell line ip, This mouse fibroblast 
cell line termed elLI03 had been transfected with a bovine papilloma virus 
based vector containing the human IL-3 gene, It was maintained in RPMI 
1640 (Gibco, Paisley, Scotland, UK) containing 10% FCS, IL-3 is present at 
high concentrations in the supernatant, The elLI03 cel line was obtained 
from Dr, R, W, van Leen, Gist-Brocades, Delft, The Netherlands, 
Tissue collections and analysis 
SCID mice were killed by C02 inhalation and cervical dislocation in accor-
dance with institutional animal research regulations, Cell suspensions were 
prepared from PB, BM, spleen and abdominal tumors, To determine the per-
centages of human myeloid cells samples obtained from BM, PB, spleen or 
tumors were incubated with fluorescein isothiocyanate (FITC) conjugated 
monoclonal antibody (MoAb) to CD45 (human common leukocyte antigen) 
and a phycoerythrin (PE) conjugated MoAb to CD33 from Beckton Dickin-
son (San Jose, CA, USA), To reduce nonspecific binding cells were stained 
in the presence of human IgGlkappa 10pg/mL (Sigma, St, Louis, MO, 
USA) and 1 % rabbit serum in phosfate buffered saline for 30 minutes on 
ice, Mouse IgGl FITC and mouse IgGl PE conjugated antibody (Beckton 
Dickinson, San Jose, CA, USA) and samples from non-transplanted SCID 
mice were used as control. Fluorescence was measured using a FACSCAN 
flow cytometer and Lysis II software (Beckton Dickinson, San Jose, CA, 
USA), Erythrocytes and dead cells were excluded from analysis by gating on 
forward and orthogonal light scatter, Only cells that stained with CD33 and 
CD45 simultaneously were counted as human myeloid cells (15), 
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IL-3 level assay 
Plasma samples of the SCID mice were assayed for IL-3 levels by using a 
commercially available kit for ELISA (Medgenix, Fleurus, Belgium). The 
detection limit was 0.050 nglml. IL-3 levels were also determined in an in 
vitro bioassay employing the IL-3 responsive cell line M-07e. Sx10' M-07e 
cells were cultured for three days in 100pL RPMI in 96 wells microtiter pla-
tes with or without plasma samples obtained from the SCID mice and triti-
ated thymidine stimulation was measured. Radioactivity was determined 
with a 1205 betaplate scintillation counter (Beckman, Fullerton, CA, USA). 
All experiments were performed at three dilutions in triplicate. In each expe-
riment standard dilutions of IL-3 were used as references. Samples were also 
incubated with a polyclonal rabbit anti-IL-3 antibody, generated at our 
laboratory, to exclude cell proliferation not mediated by IL-3. The detection 
limit of the bioassay was 0.1 nglml. 
RESULTS 
In vitro growth of AML cell samples 
Autonomous growth was present in AML case D only. Cells from AML 
cases A, Band C did not show autonomous proliferation in vitro. All four 
samples from AML cases A thm D showed positive IL-3 responses in vitro 
(Table I). Influence of total body irradiation and transplantation route on 
HL-60 engraftment in bone marrow of SCID-mice. 
To investigate the dose of TEl and to compare iv and ip transplantation, 
groups of SCID mice were irradiated with 0, 2, 3 or 4 Gy of TEl and trans-
planted iv or ip with Sx10' HL-60 cells (Table II). 
Table I 
3H-Thymidine uptake ill serum-free culture with and without IL-3 support 
AML FAB cytogenetics No IL-3 IL-3 IL-3 
dpmx10·2 dpmxl0·2 responder 
±SD ±SD 
A M1 normal 1.0(±0.2) 46.8(±0.6) + 
B M1 normal 3.9(&4) 111.0(±S.4) + 
C MS normal 2.5(&8) 2S.8(±3.S) + 
D M4 complex 16.8"(±0.3) S2.2(±3.4) + 
Table 1. 3H-Thymidine incorporation by AML cells expressed as decayes per minu-
tel100 + or - one standard deviation (SD) was determined IInder semm-free conditions 
with or without IL-3. + : postive test * : spontalleolls tritium thymidine uptake (allto-
IIOIIIOIlS growth). FAB: AML slIbtype in the FAB classification. Cytogenetics complex: 
43XY, 2q+, -4, -7, 10q-, -17. 
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Table II 
Engraftment of HL60 ill SClD mice. Transplantation route, dose of TBl 
dose of IV route 
TEl (Gy) % day 
0 0 42 
0 0 42 
0 7 42 
0 
2 10 31 
2 23 32 
2 46 32 
2 
3 28 31 
3 61 31 
3 64 31 
3 
4 + 
4 + 
4 + 
4 
IP route 
% day 
0 31 
0 43 
2 43 
5 43 
0 35 
3 37 
0 37 
0 37 
0 31 
1 35 
0 35 
0 35 
+ 
+ 
+ 
+ 
Table II 
24 hOllrs after 0, 2, 3 or 4 Gy 
of TBI SCID mice were illjec-
ted illtravellollsly (iv) or 
illtraperitolleally (ip) with 
5xlO' hllmallmyeloid HL-60 
cells. 
+: toxic death from sepsis. 
Each percelltage represellts 
aile SCID mOllse. 
Significant bone marrow infiltration was apparent only after TEl and iv 
transplantation. For intravenous transplantation a dose effect relationship 
between TEl dose and percentage of HL60 cell engraftment in the mouse 
bone marrow (Spearman Rank test, 1'=0.82, p<0.05) was found. However, 
a TEl dose of 4 Gy resulted in death from sepsis with E. coli and/or entero-
coccus. Mice transplanted ip showed local intraperitoneal tumor growth, 
without significant BM infiltration. Similar results were obtained for the 
human myeloid cell line M-07e (data not shown). In subsequent expe-
riments we delivered 3.5 Gy of TEl and performed transplantation iv. 
AML cell dose titration 
Groups of mice were injected iv with graded numbers of AML cells (from 
patient B). Injection of 30xl06 AML cells resulted in extensive BM infiltra-
tion by human cells, which became apparent at an earlier time (day 36) than 
following lower cell doses (Table III). Recipients of 0.36xl06 cells or less 
remained free from overt disease and did not show AML cell repopulation 
as late as day 81. 
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I Table III Cell dose titration of AML 
Cell dose Unique Day of % human 
(xl0' cells) animal evaluation cells BM 
number 
30 # 1 35 91 
#2 35 8 
#3 36 79 
#4 36 35 
10 #5 20 0 
#6 20 1 
#7 36 28 
#8 36 60 
#9 36 6 
3.3 #10 36 3 
#11 36 9 
1.1 #12 36 0 
#13 36 0 
#14 47 2 
#15 61 19 Table 111 
#16 67 3 SCID mice received 3.5 
0.36 #17 81 1 Gy of TEl alld received graded doses of AML cells 
#18 81 0 derived from patiellt B 
#19 81 0 witholtt lL-3 support. 
Human IL-3 administration 
To investigate the role of growth factor support cells of one AML patient 
(case A) were transplanted into SCID mice. After transplantation graded 
doses of IL-3 were injected ip three times a week. In one group rIL-3 sup-
port was provided by injecting the IL-3 producing cell line (cILl03) in the 
peritoneal cavity. 
Significant growth of human cells was absent in animals receiving IL-3 at a 
dose of 15 llg/mouse or no IL-3 at all. In recipients of 30-6011g doses of IL-
3, repopulation of the bone marrow by up to 33% of human cells could be 
achieved, but the level of infiltration showed great variability (Table IV). 
Serum IL-3 levels determined 24 hours following IL-3 injection were below 
detection level (0.1 ng/ml in the bio-assay). Reproducibly high percentages of 
human AML cells were observed in mice cotransplanted with the IL-3 produ-
cing cell line. These mice also showed the highest IL-3 plasma levels. IL-3 
was detected early after transplantation and its plasma concentration increa-
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sed exponentially during 30-50 days to values of 20-300 ng/ml (figure I). 
cILI03 transplanted ip into SCID mice behaved as a malignant tumor resnl-
ting in metastatic growth and ascites and finally death of the recipients be-
tween days 40 and 50. 
Figure 1 IL-3 levels after transplantation of cIL-1 03 
1000 
cf' 0 
100 0 • 
• ~ 
~ B • ~ E 10 B 0 • ~ 0 Ol ~ • c El El 
B 1'1 0 1 - 0 
0 8 
0,1 I I I I I I 
0 10 20 30 40 50 60 70 
days post transplantation 
Figure 1 
SCID mice were transplanted ip on day 0 with a cell dose of 1 0' of cIL1 03 
cells after TBI. Plasma IL-3 levels were determined by ELISA (. ) or in a 
bioassay (D) in a total of 69 samples. 
Growth of AML in the SCID mouse and relation to IL-3 support 
AML cells derived from patients A, B, C and D were injected iv into scm 
mice (cell dose 30.10', 3.5 Gy TBI) and some of the mice were cotransplan-
ted with the IL-3 producing cell line cILl03. The cells from all cases engraf-
ted and repopulated in the scm mice which also received cILI03 cells 
(Table V). Between days 29-40, the mice developed clinical signs of leu-
kemia: especially anemia, rough fur and lethargic behaviour. FACS analysis 
of SCID mice BM showed extensive replacement by AML cells. The AML 
cells from patient B, which required IL-3 for growth in vitro, were also able 
to proliferate in recipients which did not receive exogenous IL-3. In contrast 
the cells from AML D showed autonomous proliferation in vitro, but were 
dependent on IL-3 in vivo. 
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TABLEN 
Stimulation of AML engraftment in SCID miee with graded doses of IL-
3 and an IL-3 producing eel/line 
IL-3 Unique Day of % human 
dose animal evaluation cells BM 
number 
none #20 29 0 
#21 29 1 
#22 46 0 
#23 47 0 
151lg #24 46 1 
#25 48 0 
#26 48 1 
30llg #27 29 22 
#28 46 1 
#29 48 0 
60llg #30 24 8 
#31 46 33 
#32 48 7 
cIL-103 #33 29 44 
#34 29 30 
#35 29 68 
#36 29 61 
#37 29 20 
#38 29 43 
TableN 
Groups of mice (3.5 Gy of TBl) tvere tral1splal1ted iv tvith 3.10' AML celfs (case A). 
They tveYe il1jected il1traperitol1ealfy three times a tveek tvith il1creasil1g doses of lL-3. 
The lL-3 producil1g celf lil1e cIL-103 tvas tral1splal1ted il1traperitol1eaffy il1 the fil1al 
cohort of mice il1 order to stimulate AML el1graftmelll. 
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TABLE V 
Humall AML growth with or without IL-3 
AML, Unique + or- Day of % human 
in vitro animal cILl03 evaluation cells BM 
growth number 
A, #33'" + 29 44 
IL-3 #34':' + 29 30 
dependent #35':' + 29 68 
#36'" + 29 61 
#37"" + 29 20 
#38'} + 29 43 
#20'" - 29 1 
#21'" - 29 1 
#22':' 
- 46 0 
#23" - 47 0 
B, #39 + 40 42 
IL-3 #40 + 40 57 
dependent #41 + 40 50 
#1'" - 35 91 
# 2" - 35 8 
# 3'" - 36 79 
# 4':' 
- 36 35 
#42 - 40 79 
#43 - 40 89 
C, #44 + 40 64 
IL"3 #45 + 46 15 
dependent #46 - 43 3 
D, #47 + 33 15 
IL-3 #48 + 33 15 
responsive #49 + 33 18 
and #50 - 33 2 
autonomous #51 - 33 2 
Table V 
Growth of humall AML ill SCID mice with or without IL-3 support. AML cells from 
four differellt patiellt were trallsplallted iv illto SCID mice (graft size 30.10' AML cells, 
3.5 Gy of TBI). III vitro three alit of four AMLs were IL-3 depelldellt (AML A, B alld 
C), aile also showed autollomous growth (AML D). Groups of SCID mice were cotralls-
plallted with elL-1 03, all IL-3 producillg cell-lille. *data from earlier experiments, repor-
ted ill Table III alld IV. 
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DISCUSSION 
Conditions required for optimizing engraftment of AML in SCID mice were 
investigated: the role of pre transplant conditioning, of route of transplanta-
tion, of the graft size of AML and stimulation of AML growth by IL-3 
administered in vivo after transplantation. 
Results of experiments with the cell line HL-60 demonstrated that iv trans-
plantation allowed for engraftment and extensive AML growth in BM in 
contrast to ip transplantation. For intravenous transplantation, a dose effect 
relationship between dose of TBI and growth of human AML cells in the 
mouse BM is apparent. The effect of TBI may be mediated by immunosup-
pression or by the creation of space (16). As NK-cell and LAK-cell function 
are retained in SCID mice, immunosuppression directed against these cells 
may facilitate engraftment further. Obviously there should be sufficient 
space in the hemopoietic tissue for the incoming graft, since transplantation 
of feasable numbers of syngeneic myeloid cell lines is impossible without 
creating space (17), similar to syngeneic bone marrow (18). 
Transplantation of doses of 30xl0' cells may lead to rapid outgrowth of 
AML. Howevel; it should be noted that at days 40-80 AML cells were also 
detected in mice injected with low cell doses. This demonstrated the long 
term viability and proliferative potential of AML cells in the SCID mouse. 
It also indicates that the abscence of detectable AML before day 40 is not 
necessarily due to graft failure. The minimum cell dose necessary for repro-
ducible engraftment was 1.1xl0' AML cells. A minimal cell dose of 2xl0' 
cells was observed by others (2). This may indicate that the minimum requi-
red cell dose varies for different cases of AML. 
Data on the use of hHGFs to stimulate normal human hematopoiesis in the 
SCID mice are scarce (19,20,21), but generally administration of hHGF,s 
resulted in stimulation of growth of human hematopoiesis. Mast-cell 
growth factor (c-kit ligand) and PIXY321 were shown to stimulate growth 
of AML in scm mice (2). Among 17 cases, in 16 instances AML engraft-
ment was apparent. However the quantitative level of engraftment varied 
considerably and 14% of the mice showed less than 10% human cells 
engrafted. Here we show that reproducible growth of AML, supported by 
the cotransplanted IL-3 producing cell line, in all foUl' cases overgrew the 
mouse bone marrow. This resulted in clinical signs and symptoms of acute 
leukemia. Lack of growth of AML A, C and D without IL-3 supply appa-
rently demonstrates IL-3 dependence in vivo. 
OUl' results indicate that the required rh-IL3 dose is relatively high: i.e. more 
than 60pg ip three times per week. Intraperitoneal cotransplantation of 
cILI03 results in earlier and more extensive growth of AML. This growth 
advantage is probably caused by the high and continuous IL-3 plasma levels 
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achieved in these mice (figure I). The use of cILI03 as a source of IL-3 in 
vivo is relatively easy and reduces the need for purified IL-3. However, the 
ccll line in vivo shows the characteristics of a malignant tumor. SCID mice 
die from the tumor after about 50 days, ultimately interfering with the expe-
riments on AML growth. As human AML growth in vitro can be stimulated 
by other hematopoietic growth factors one may assume that AML growth 
in the SCID mouse supported by IL-3 can be augmented by GM-CSF, G-
CSF, stem cell factor or other cytokines stimulating AML proliferation in 
culture. 
In vitro IL-3 dcpendency of AML cells (as assessed with activation of DNA-
synthesis in vitro) was not predictive for the dependency on IL-3 in vivo. 
The AML cells of patient B were IL-3 dependent in vitro but did not requi-
re IL-3 in vivo. Perhaps these AML cells supply their own cytokines when 
cngrafted into mouse bone marrow stroma or they may grow truly autono-
mously. Similar results, in vivo growth without hHGF support and in vitro 
hHGF depcndency, were found for the human myeloid cell line M-07e. In 
contrast, the AML cells of patient D grew autonomously in vitro but clear-
ly needed IL-3 in vivo. The reasons for the discrepancy between in vitro and 
in vivo responsiveness to IL-3 remain to be investigated. 
Apparently proliferation of cells from the majority of acute myeloid leu-
kemias can be achieved and maintained in SCID mice for a more extended 
period of time than in culture. This expands the possibilities to study in 
particular long term growth of AML. 
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ABSTRACT 
Transplantation of normal and malignant hnman hematopoietic cells into 
severe combined immunodeficient (SCID) mice allows for evaluation of 
long term growth abilities of these cells and provides a preclinical model for 
therapeutic interventions. Howevel, large numbers of cells are required for 
successful engraftment in preirradiated mice due to residual graft resistance, 
that may be mediated by cells from the mononuclear phagocytic system. 
Intravenous (iv) injection of Iiposomes containing dichloromethylene dip-
hosphonate (CI2MDP) may eliminate mouse macrophages in spleen and 
liver. In this study outgrowth of acute myeloid leukemia (AML) cells and 
umbilical cord blood (UCB) cells in SCID mice conditioned with a single iv 
injection of Cl2MDP-liposomes in addition to sublethal total body irradia-
tion (TEl) was compared to outgrowth of these cells in SCID mice that had 
received TBI alone. 
In four cases of AML, a 2-10 fold increase in outgrowth of AML cells was 
observed. Administration of 10' UCB cells reproducibly engrafted SCID 
mice that had been conditioned with Cl2MDP-liposomes and TEl, whereas 
human cells were not detected in mice conditioned with TBI alone. As few 
as 2x10' purified CD34+ UCB cells engrafted in all mice treated with 
CI2MDP-liposomes. Unexpected graft failures were not observed among 
SCID mice treated with macrophage depletion. Histological examination of 
the spleen showed that TEl and Cl2MDP-liposomes iv resulted in a trans-
ient elimination of all macrophage subsets in the spleen, whereas TEl had a 
minor effect. Cl2MDP-liposomes were easy to use and their application was 
not associated with appreciable side-effects. Cl2MDP-liposome pretreat-
ment in combination with TBI allows for reproducible outgrowth of high 
numbers of human hematopoietic cells in SCID mice. 
INTRODUCTION 
Severe combined immunodeficient (SCID) mice may be used as a model for 
the in vivo analysis of proliferation of human hematopoietic cells. (1-5) In 
hematological diseases such as acute myeloid leukemia (6,7), chronic mye-
loid leukemia (8), acute lymphoblastic leukemia (9,10,11) and lymphoma 
(12) SCID mice provide a useful model for analysis of long-term growth and 
therapeutic interventions in vivo.(13,14,15) Conditioning of scm mice 
using sublethal TEl and intravenous transplantation allows for outgrowth 
of these cells in the SCID mouse bone marrow. (1,16) 
Howevel, even following sublethal irradiation of SCID mice large numbers 
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of human hematopoietic cells are required for reproducible outgrowth and 
graft failures are frequently observed. (1-3,5-15) These problems restrict the 
practical possibilities for analysis of subsets of hematopoietic cells. As SCID 
mice are T and B cell deficient, likely explanations for residual graft resi-
stance may be that transplanted human hematopoietic cells are cleared by 
either recipient mononuclear phagocytes or by recipient NK cells. (17,18) 
Macrophage depletion with the purpose of facilitating engraftment of allo-
geneic and xenogeneic bone marrow grafts has been investigated before, 
using less specific means such as silica or carageenan. In irradiated mice, 
carrageenan and silica abrogated or weakened resistance to parental, allo-
geneic and rat marrow grafts. (19-22) However, both carrageenan and sili-
ca are highly toxic agents. Furthermore, they do not completely eliminate 
macrophages and exert undesired effects on non-phagocytic cells. 
(19,21,23)These disadvantages clearly compromise their applicability in 
bone marrow transplantation in general and in the SCID mouse model in 
particular. In vivo macrophage depletion has been achieved with Iiposomes 
which contain c1odronate (CI2MDP). Such liposomes are ingested by 
macrophages. After intracellular disruption of the Iiposomes c1odronate 
effectively kills these cells. (24) Which population of macrophages is elimi-
nated depends on the route of administration of CI2MDP-liposomes. (25) 
Intravenous injection of the liposomes mainly eliminates phagocytic cells in 
liver and spleen, the candidate effector cells in graft resistance, because of 
their direct contact with circulating hematopoietic cells. Fraser et al. (26) 
showed that intravenous injection of Cl2MDP-liposomes into unirradiated 
SCID mice prolonged the time needed for clearance of intravenously injec-
ted human peripheral blood lymphocytes. Similarly, application of these 
liposomes to SCID mice with an established human thymus/liver graft resul-
ted in increased numbers of circulating human lymphocytes. To determine 
the effect of Cl2MDP-liposomes on engraftment of normal and leukemic 
human hematopoietic cells in irradiated SCID mice we compared trans-
plantations with or without additional CI2MDP Iiposome treatment. 
MATERIALS AND METHODS 
Acute myeloid leukemia cells and umbilical cord blood cells 
Peripheral blood (PB) samples were obtained following informed consent 
from four patients presenting with AML, diagnosed according to the criteria 
of the French-American-British Committee (FAB). (27) AML cells and 
umbilical cord blood samples (UCB) were isolated by Isopaque-Ficoll cen-
trifugation (1.077g/cm'; Nycomed, Oslo, Norway) and then cryopreserved. 
(28) After thawing the viability of AML and UCB cells as assessed by try-
pan blue exclusion was always>70%. 
42 
Preparation of CD34+ umbilical cord blood fractions 
UCB cells were incubated with an IgG2a antibody against CD34 (MoAb 
561) which was noncovalently linked to rat-anti-mouse 19G2a-conjugated 
immunomagnetic beads (Dynabeads, Dynal, Oslo, Norway). CD34+ cells 
were eluted from the beads using a polyclonal antibody preparation direc-
ted against the Fab fragment of the CD34 antibody (Detachabead, Dynal). 
(29) 
Immunodeficient mice and transplantation of AML alld umbilical cord 
blood (UCB) 
Female specific pathogen-free CB17 scid/scid mice (5-9 weeks of age) were 
purchased (Harlan CPB, Austerlitz, The Netherlands). Non obese diabetic 
scm (NOD/SCm), specifically NOD/Lt-SCm/Sz mice (11 weeks of age), 
were obtained from Jackson Laboratories, Bar HarboU1; MA. Housing, 
total body irradiation (TEl) and transplant procedures have been described. 
(16) AML #1 and AML#2 engrafted in scm mice without support of 
human hematopoietic growth factors and AML#3 and #4 were 1L-3 depen-
dent in scm mice. The latter scm recipients received 60pg of human 1L-3 
(Gist Brocades, Delft, The Netherlands) in 200pL HBSS and 1 %BSA 
(Sigma) intra peritoneally, five days a week as described. (16) Mice trans-
planted with UCB did not receive growth factor treatment. 
Liposome preparation 
Cl2MDP-liposomes were prepared as reported. (30) Briefly, 75mg phosp-
hatidyl choline (Lipoid GmbH, Ludwigshafen, Germany) and llmg choles-
terol (Sigma, St Louis, MO) were dissolved in chloroform in a round bot-
tom flask. After low vacuum rotary evaporation at 37°C the lipids were dis-
persed by gentle rotation in 10ml PBS in which 2.5mg c1odronate (a gift of 
Boehringer Mannheim, GmbH Mannheim, Germany) was dissolved. The 
resulting liposomes were washed twice at 100,000g for 30 minutes to remo-
ve free, non-entrapped diphosphonate. The liposomes were then resuspen-
ded in 4mL phosphate buffered saline (PBS) (liposome stock solution). scm 
mice were injected in a lateral tail vein with 0.2mL liposome stock solution 
on the day before transplantation of the hematopoietic cells. 
Tissue collections 
scm mice were killed by C02 inhalation followed by cervical dislocation 
in accordance with institutional animal research regulations. Cells or tissu-
es from cohorts of mice transplanted with the same graft were evaluated, 
between days 22 and 47 after transplantation using flow cytometry and 
cytology. (31) Spleens of selected mice were extirpated and cryostat sections 
were prepared for pathologic examination. 
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Flow Cytometry 
To determine the percentage of human hematopoietic cells in the SCID 
mouse, bone marrow samples from mice that had been transplanted with 
UCB grafts were incubated with mouse monoclonal antibodies to human 
CD33 , CD34, CD45 and CD38. The initial leukemias and BM samples 
from mice that had been transplanted with leukemic grafts were stained or 
double-stained with the following mouse monoclonal antibodies ): CD34-
FITC, CD34-PE, CD38-PE, CD34-FITClIgGI-PE, CD34-FITCICD38-PE, 
CD34-FITCIHLA-DR-PE, CD34-FITC/c-kit-PE, CD34-FITCICD33-PE and 
finally CD45-FITCICD33-PE. Mouse IgGl-FITC and mouse IgGI-PE con-
jugated antibodies and samples from non-transplanted SCID mice were 
used as controls. c-kit-PE was purchased from Immunotech, Marseille, 
France, all other antibodies from Becton Dickinson, San Jose, CA, USA. The 
phenotypes of cells recovered from the SCID mouse bone marrow was com-
pared to those of the grafts. Fluorescence was measured using a FACSCAN 
flow cytometer and Lysis II software (Becton Dickinson, Immunocytometry 
Systems). Erythrocytes and dead cells were excluded from analysis by gating 
on forward and orthogonal light scatter. Cells recovered from SCID mouse 
bone marrow (BM) with positive staining for two antibodies specific for 
human hematopoietic cells were considered to be graft derived. (32) 
Immunohistochemistry of spleen sectio11s 
Freshly obtained SCID mouse spleens were embedded in Tissue-tek II (Miles 
Laboratories, Inc., Naperville, MI), frozen and stored at -70'C. Cryostat 
sections of 5pm were prepared. Tissue fixation and immunoperoxidase stai-
ning of cryostat sections were performed essentially as described by de Jong 
et a1. (33) For fixation a hexazotized pararosaniline solution (0.5mL, 4%) 
was added to NaN02 (0.5mL, 4%), diluted in 165mL sterile water and 
applied to dry tissue sections (2 minutes) followed by washing in PBS. (33) 
MAb binding was detected using a modified protocol involving NiS04-sup-
plemented DAB and counterstaining of the nuclei with nuclear fast red. (34) 
Sections were incubated with a panel of monoclonal antibodies to determi-
ne the effect of TBI and TEl with macrophage depletion by Cl2MDP on 
macrophage subsets in the spleen as representatives of phagocytic cells in 
direct contact with the blood stream. The antibodies used were F4/80 
(35,36) (identifying especially red pulp macrophages), ER-HR3 (37,38) 
(major subset of red pulp macrophages), ER-TR9 (39,40) (marginal zone 
macrophages), MOMA-l(41) (marginal metallophilic macrophages), 
Monts-4 (42) (marginal metallophilic and white pulp macrophages) and 
N418 (anti-CDllc) (43,44) (dendritic cells). To confirm results with other 
antibodies in addition BM8 (45) (red pulp macrophages), SERA (46) (mar-
ginal metallophilic macrophages) and ER-BMDM1 (47) (dendritic cells) 
were applied. 
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RESULTS 
Pretreatment with Cl2MDP-liposomes enhances engraftment of AML 
We examined the effect of additional Cl2MDP liposome treatment on the 
engraftment abilities of AML cells (from case #1-4) in SCID mice treated 
with TEl and liposomes versus TEl alone (controls). Liposome treatment in 
addition to TEl resulted in an increase in the percentages of leukemic cells 
in the mouse bone marrow (BM) by 2-10 fold (Table 1). Leukemic tumor 
load per mouse increased 3-12-fold (Table 1). Graft failure was defined as 
less than 0.5% of AML cells in the SCID mouse BM. Among the 25 mice 
transplanted with AML cells following liposome treatment no graft failures 
were observed, whereas six graft failures were seen in control recipients 
(p=0.02, Fisher's Exact Test) (Table 1). The immunophenotypes of the leu-
kemic cells recovered from the ScrD mice (as assessed by flow cytometry) 
were identical to those of the original grafts. 
Comparison of growth of AML in SCID mice and in NODISCID mice 
The outgrowth of graded cell doses of AML #Z in scm mice pretreated 
with Cl2MDP liposomes was comparable with that in NOD/SCID 
mice.(Table 2). 
Macrophage depletion enhances outgrowth of vCB cells in SCID mice 
Enhancement of engraftment of normal human hematopoietic cells was 
assessed in cell dose titration experiments of UCB cells. Transplantation of 
10xl0' UCB cells after TEl did not allow for reproducible engraftment 
(Table 3). By comparison grafts of only lxl0' UCB cells engrafted in 5 of 6 
scm mice prepared with additional macrophage depletion. Thus an 
approximately 10-fold reduction of the minimal cell numbers required for 
engraftment was seen as a consequence of additional conditioning with 
Cl2MDP liposomes. (Table 3). Cell dose titrations with CD34+ selected 
UCB cells were performed in mice conditioned with TEl and macrophage 
depletion. As few as 10xl0' CD34+ UCB cells reproducibly engrafted scm 
mice (data not shown). 
Extensive depletion of all spleen macrophage subsets by the combination of 
Cl2MDP liposomes and TBl, limited effect of TBl alone 
To evaluate the effect of CIZMDP liposomes on SCID mouse macrophages, 
which are possibly involved in scavenging of transplanted human hemato-
poietic cells, cryostat spleen sections were incubated with a panel of anti-
bodies identifying distinct mononuclear phagocyte subpopulations. TEl at 
3.5 Gy without administration of CIZMDP-liposomes had negligible effects 
on macrophage subpopulations in the spleen at day 4 after conditioning. 
Red pulp, white pulp and marginal zone macrophage populations identified 
Table I Growth of human AML cells in SCID mice: effect of pretreatment with Cl2MDP liposomes 
AML#l AML#l AML#2 AML#3 AML#4 
Cell numbers 
transplanted 1 10 10 20 30 
(xl0') 
conditioning MD TBI MD TBI MD TBI MD TBI MD TBI 
+TBI +TBI +TBI +TBI +TBI 
% of AML cells 76=18 Ih16 9h5 4h43 19:18 7:6 63:17 25:22 10=13 hI 
in SCID BM 
(mean :SD) 
AML 24:8.52.0:2.1 58:12 23:27 11:11 3:3 44:10 8:7 2:1 0.3:0.4 
tumor load"' (xl0') 
(mean:SD) 
graft failures 0/8 117 0/5 0/5 0/5 1/5 0/4 1/3 0/3 3/5 
!transplanted 
SCID mice 
Table I 
Irradiated groups of SCID mice (3.5Gy) were transplanted with cells from 4 cases of AML with or without CI?MDP 
pretreatment and evaluated on the same day, between days 35 and 47. 
''The tumor load was determined by counting the number of nucleated cells obtained by flushing of two mouse femora, 
equivalent to 13.5% of the total mouse bone marrow (50) as well as the percentages of human hematopoietic cells deter· 
mined by flow cytometry. 
Abbreviations: BM: bone marrow, SD: standard deviation. MD: macrophage depletion by pretreatment with Cl2MDP 
liposomes, TBI: total body irradiation 
"-----~~ 
I 
i 
"'" 
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by immunophenotypic analysis had not changed significantly (Table 4). 
In contrast, dendritic cells (identified by the monoclonal antibodies N418 
and ER-BMDM1) had disappeared from the red pulp and from the white 
pulp as a consequence of the sublethal dose of TBI alone. Combined treat-
ment with TBI and Cl2MDP liposomes depleted all identifiable macropha-
ges from the white pulp, the red pulp and the marginal zone (Table 4). At 
day 45 after transplantation, all mononuclear phagocyte subsets had reap-
peared except ER-TR9 positive marginal zone macrophages. (Table 4). 
Table II 
Cell dose titration of AML #2 in SCID mice with and without 
Cl2MDP liposome pretreatment and in NODISCID mice 
Conditioning MD+TBI TBI TBI 
Animals scm mice scm mice NOD/SCm mice 
Cell numbers 
transplanted 
(xl0') 
30 77 
93 
10 81 19 45 
56 38 36 
69 66 
3.3 83 3 34 
7 1 34 
32 3 33 
31 
1 1 0 7 
4 0 2 
5 0 13 
2 
0.3 0.2 5 
4 
Table 11 
NOD/SCID mice were trallsplallted ill the same eXjJerimellt as the SCID mice. All 
mice were evall/ated all days 28 alld 29. Data represellt percelltage of illfiltratioll of 
hI/mali cells ill the bOlle marrow of illdividl/almice. Abbreviatiolls: BM: bOlle marrow, 
MD: macrophage depletioll by pretreatmellt with Cl2MDP liposomes, TBI: total body 
irradiation 
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Toxicity of Cl2MDP-liposomes 
The injection of 0.2mL of Cl2MDP-liposomes on the day before TBI and 
transplantation did not result in appreciable side effects during the 45 day 
observation interval. Among the 56 mice conditioned with TBI alone 6 ani-
mals died before evaluation (11 %). In comparison 6 deaths were noted 
among 91 mice conditioned with TBI and additional macrophage depletion 
(8%). 
Table III Cell dose titration of 2 umbilical cord blood samples 
in SCID mice with and without Cl2MDP pretreatment 
UCB#1 UCB#2 
Conditioning MD+TBI TBI MD+TBI TBI 
Cell numbers 
transplanted 
(xl0') 
30 71 75 
56 
10 24 1 11 0 
6 0 18 0 
11 0 12 1 
6 0 6 0 
3.3 9 0 3 0 
3 0 0 0 
9 0 1 0 
0 
1 1 1 
1 3 
11 
0 
Table III 
Irradiated SClD mice were transplanted with graded doses of IImbilical cord blood 
cells with or withollt macrophage depletion. Data represent {)ercentage of infiltration 
of hllman cells in the bone marrow of individllalmice. All mice were evaillated 011 
days 41 alld 42. 
Abbreviatiolls: ND: 1I0t dOlle, UCB: IImbilical cord blood graft MD: macro{)bage 
depletioll by pretreatment with Cl2MDP liposomes, TBl: total body irradiation 
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Table N Macrophage populations ill the spleen of SCID mice after TEI 
or TEl and macrophage depletion. 
Antibodies spleen Control Day 4 Day 45 
regIOn TEl MD TEl . MD 
+TEl +TBI 
F4/80 wp 2+ 4+ 0" 1+ 2+ 
rp 4+ 4+ 0':' 4+ 4+ 
ER-HR3 wp 1+ 1+ 0 1+ 2+ 
rp 3+ 3+ 0 3+ 3+ 
ER-TR9 mz 2+ 1+ 0 0 0 
MOMA-1 pwp 3+ 2+ 0 3+ 2+ 
rp 2+ 3+ 0 1+ 1+ 
Monts-4 wp 3+ 3+ 0 3+ 2+ 
rp 1+dim 2+ 0 1+ d+ 
N418 wp 4+ 0 1+ 3+ 4+ 
mz 2+ 1+ 0 2+ 3+ 
rp 1+ 0 0 1+ 1+ 
-
Table IV To determine the effects of TBl and macrophage depletioll by Cl2MDl' lipo-
somes all splee/l macrophage polJIIlations SClD mice were evaillated on days 4 alld 
45 after TBI, and compared to IIntreated SClD mOllse controls. The data obtained 
with these antibodies were similar to data obtained with the lise of the independent 
antibodies BM-S, SER-4, and ER-BMDMI (data not shown). 2 or 3 mice per grollp 
were evaluated. 
Abbreviations: TBl total body irradiation, MD: macrophage depletion by pretreatment 
with Cl2MDP liposomes, lOP: white pilip; rp: red pilip; pwp: peripheral white pilip; mz: 
marginal zone. The nllmber of macrophages staining with a specific antibody within 
these anatomically defined regiolls were scored semiqllallfitatively: 4+: >50% positivity-
conf/uellt; 3+: 50%; 2+: 10% - 50%; 1+: scarce. >;"= 011/Y remna1lts 
DISCUSSION 
Macrophage depletion by intravenous administration of CI2MDP-liposo-
mes prior to sublethal TBI enhances the engraftment of human hemato-
poietic cells in the ScrD mouse bone marrow. This treatment is easy to 
apply and without significant toxicity. Outgrowth of primary human AML 
increased 2-10 fold and engtraftment of umbilical cord blood cells was 
achieved with at least 10 fold smaller grafts (Tables 1 and 3). Probabilities 
of graft failure were significantly reduced (Table 1). Thus, conditioning with 
TBI and Cl2MDP-liposomes in combination permits the establishment of 
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relatively small human hematopoietic cell grafts, e.g. lxlO' unseparated 
UCB cells or lxlO' CD34 positive UCB cells and may facilitate the use of 
the SCID mouse model for the study of normal and malignant human hema-
topoietic cells. 
The observations suggest a functional role of murine phagocytic cells in the 
clearance of human hematopoietic cells that engraft SCID mouse bone mar-
row, similar to the delayed clearance of human lymphocytes from the SCID 
mouse circulation as observed by Fraser et al. (26) Other more indirect 
immunological mechanisms cannot be excluded. One of these mechanism 
relates to the modulation of NK cell function by macrophages. Depletion of 
macrophages in the liver (Kupffer cells) with Cl2MDP-liposomes was asso-
ciated with a parallel decrease of the number of NK cells. (48) Furthermore 
Kupffer cell conditioned media appeared to enhance NK cell viability and 
function in vitro. (48) In the study by Fraser et al. (26) complete depletion 
of macro phages in the red pulp of the spleen was observed while many 
white pulp macrophages remained. Our data show that white pulp macrop-
hages are eliminated by Cl2MDP-liposomes in sublethally irradiated mice. 
NOD/SCm mice have multiple immunological defects. In addition to Band 
T cell deficiency, NK function is absent and these mice may also have a 
macrophage maturation defect. (49) It has been shown that the tumor load 
in the spleen of SCIDINOD mice transplanted with human CEM T Iymp-
hoblasts was increased 4-fold as compared to similarly transplanted SCID 
mice. (49) Our results indicate that the outgrowth of AML and UCB grafts 
in irradiated scm mice conditioned with additional Cl2MDP-liposomes 
may be as effective as that in sublethally irradiated NOD/SCm mice. 
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ABSTRACT 
Acute myeloid leukemia (AML) proliferation in vivo is maintained by a 
small fraction of progenitor cells. These cells have been assumed to express 
an immature phenotype and to produce most colony forming units (AML-
CFU). For one case of AML (FAB Ml, normal cytogenetics) we examined 
the capacity of the CD34+ (25% of unseparated AML cells) and CD34-
fractions to initiate leukemia in severe combined immunodeficient (SCID) 
mice. In addition, the production of AML-CFU and nucleated cells (NC) of 
these subsets was investigated in long term bone marrow culture (LTBMC). 
The frequencies of cobblestone area forming cells (CAFC) were also esti-
mated; early appearing cobblestone areas (CAs) being indicative of relative-
ly mature progenitors and late CAs representing the progeny of primitive 
progenitors. In mice transplanted with CD34- (98% pure) or CD34+ (98% 
pure) grafts, similar AML cell growth was seen throughout an observation 
period of 106 days. The capacity to establish long term growth from the 
CD34- cells was confirmed by renewed outgrowth after retransplantation. 
In vitro, the CD34- fraction contained both immature and mature CAFCs 
and produced high numbers of AML-CFU and NC in LTBMC. The CD34+ 
fraction produced only small numbers of AML-CFU, NC and mature 
CAFCs. Therefore, the expression of CD34 and the content of AML-CFU 
were not associated with long term growth of AML. However, similar fre-
quencies of primitive CAFCs were observed in both fractions. Thus, both 
CD34- and CD34+ subsets of this AML sample contained immature proge-
nitors with the capacity to initiate long term AML growth as characterized 
in vivo (in SCID mice) as well as in vitro (in CAFC assay), indicating asyn-
chrony between functional and immunophenotypical maturation of AML 
progenitor cell compartments. 
INTRODUCTION 
The malignant cell population of acute myeloid leukemia (AML) is assu-
med to be maintained in vivo by a small fraction of cIonogenic cells (1). 
Analysis of this fraction so far has been hampered by lack of assays for long 
term growth of AML. Long term growth of normal human bone marrow 
can be demonstrated in vitro, for example by long term bone marrow cul-
tures (LTBMC). Clonogenic AML cells have mainly been studied as colony 
forming units of AML (AML-CFU) in short term colony assays. Although 
the immunophenotype of AML-CFU displayed considerable heterogeneity 
among patients and may be aberrant (2-7) cIonogenic capacity is generally 
regarded to be associated with an immature phenotype. The appearance of 
CD38 and the loss of CD34 expression have been associated with the loss 
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of clonogenic capacity (8,9). 
Recently, CD34 and CD38 expression of in vivo leukemia initiating cells has 
been investigated in mice with Severe Combined Immunodeficiency (SCID). 
In one case leukemia was shown to be initiated in mice injected with the 
CD34+/CD38- AML cell fraction (10). AML was not established from the 
AML fraction depleted of the CD34+/CD3 8- cells. The data suggest that the 
heterogeneous marker expression of AML allows for isolation of fractions 
containing high numbers of progenitors, similar to normal hematopoietic 
cells. 
To examine long term growth of AML cells, we used transplantation in 
SCID mice as well as the cobblestone area forming cell (CAFC) assay. This 
assay allows for calculation of clonogenic cell frequencies in fractions of 
hematopoietic cells. The late appearing cobblestone areas (CAs) of normal 
hematopoiesis are considered stem cell progeny with long term engraftment 
potential, whereas the early appearing CAs are assumed to be derived from 
more mature progenitors (11). 
The capacity to initiate leukemia in vivo in SCID mice, the expression of 
CD34 and in vitro clonogenic growth were investigated in this study. For 
this purpose, CD34+ and CD34- cells of one AML case were transplanted 
into SCID mice and investiga ted by long term bone marrow cultures 
(LTBMC), CAFC assay as well as by short term colony cultures. 
MATERIALS AND METHODS 
AML cells 
Peripheral blood (PB) samples were obtained following informed consent 
from a patient presenting with AML Ml diagnosed according to the criteria 
of the French-American-British Committee (FAB) (12). Cytogenetics 
showed a normal karyogram. Mononuclear cells were isolated by Isopaque-
Ficoll centrifugation. Subsequently T cells were depleted by E-rosetting (13). 
The cells were cryopreserved in 10 % dimethylsulfoxide, 20% heat-inacti-
vated fetal calf serum (FCS) and Iscoves modified Dulbecco,s medium 
(IMDM). After thawing by stepwise dilution (14), viability assessed by try-
pan blue staining was always> 90%. 
Flow Cytometry 
The samples were incubated with PE-conjugated mouse monoclonal antibo-
dies against CD13, CD33, CD38, CD34 or HLA-DR and fluorescein iso-
thiocyanate (FITC) conjugated antibodies against CD15, CD34 or CD45. 
Mouse IgGI-FITC and mouse IgGI-PE conjugated antibodies and samples 
from non-transplanted SCID mice were used as controls. The antibodies 
were obtained from Beckton Dickinson, San Jose, CA, USA. Fluorescence 
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was measured using a FACSCAN flow cytometer and Lysis II software 
(Beckton Dickinson, Immunocytometry Systems). Erythrocytes and dead 
cells were excluded from analysis by gating on forward and orthogonal light 
scatter. Cells recovered from SCID mouse bone marrow (BM) staining si-
multaneously for CD33 and CD45 were counted as human myeloid cells 
(15). 
In some cases human cells were separated from the mouse BM using 
f1uoresence activated cell sorting. Cells were recovered from the SCID mou-
se BM under sterile conditions and incubated with CD3S-PE (Beckton-
Dickinson). Sorting was performed using a FACS Vantage (Beck ton-
Dickinson Immunocytometry Systems). The setting of the sorting window 
was as shown in Fig 2B. 
Preparation of CD34+ and CD34- fractions 
AML cells were incubated with an IgG2A antibody against CD34 (MoAb 
561 (16)) which was noncovalently linked to rat-anti-mouse IgG2a-conju-
gated immunomagnetic beads (Dynabeads, Dynal, Oslo, Norway). CD34+ 
cells were eluted from the beads using a polyclonal antibody preparation 
directed against the Fab fragment of the CD34 antibody (Detachabead, 
Dynal) (17). The eluted cell population was devoid of CD34 antibodies and 
was 98% CD34+ as determined by FACS analysis after restaining with 
CD34-PE (HPCA-2, Beckton Dickinson, San Jose, CA, USA) (Fig 1b). Non-
bound cells were further depleted by a similar second incubation with the 
CD34 immunomagnetic beads. In the final CD34- fraction, 2% of the cells 
weakly stained with CD34-PE (Fig 1c) in a FACScan reanalsis. 
SCID Mice and transplantation of AML 
Female specific pathogen-free CBl7 scid/scid mice (5-S weeks of age) were 
obtained from Harlan CPB, Austerlitz, The Netherlands and housed under 
pathogen-free conditions in a laminar air flow unit, and supplied with steri-
le food and acidified drinking water with 100mgIL ciprofloxacine (Bayer 
AG, Leverkusen, Germany). Before transplantation, the mouse plasma Ig 
level was determined with an ELISA using a sheep anti-mouse antibody 
reacting with mouse IgG and IgM (Boehringer Mannheim Biochemica, 
Penzberg, Germany). Mice with plasma Ig levels over 40pg/ml were exclu-
ded. 3.5 Gray of TBI was delivered by a 137Cs source (Gammacell, Atomic 
Energy of Canada, Ottawa, Canada) adapted for the irradiation of mice. 
Leukemic cells, suspended in 300pl Hanks balanced salt solution (HBSS) 
(Gibco, Breda, The Netherlands), were injected intravenously (iv) into the 
lateral tail vein. This particular AML was known to proliferate in SCID 
mice without administration of human hematopoietic growth factors (1S). 
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Tissue collections 
SCID mice were sacrificed by C02 inhalation followed by cervical disloca-
tion in accordance with institutional animal research regulations. Cell sus-
pensions were prepared from the BM and used for flow cytometry and the 
preparation of cytospin slides. Cytospin slides were stained with May-
Griinwald Giemsa and morphology was microscopically evaluated. 
Colony culture assay 
Cells (5x 10') were plated in 35-mm dishes ( Beckton Dickinson, San Jose, 
CA, USA) in ImLa-MEM (Gibco, Gaithersburg, MD, USA) containing 
0.8% methylcellulose, 5% fetal calf serum (FCS), I % bovine serum al-
bumen (BSA), glutamine (2mMlL), insulin (10pg/mL), linoleic acid, and 
cholesterol (1.5x 1O-5M1L), sodium selenite (Ix 10'MIL, nucleosides (each at 
Img/mL), 2-mercaptoethanol (Ix 10'MlL), iron saturated human transfer-
rin (0.6mg/mL), penicillin (100U/mL) and streptomycin 850pG/mL). 
Assays were performed either without hematopoietic growth factors, or 
with granulocyte-macrophage stimulating-factor (GM-CSF) (Behringwerke 
AG, Marburg, Germany, 5ng/mL), interleukin-3 (IL-3) (Sandoz BV, Basel, 
Switzerland, 10ng/mL) , GM-CSF and IL-3 or with stem-cell factor (SCF) 
(Immunex, Seattle, WA, USA, 200ng/mL), GM-CSF and IL-3. 
Long Term Bone Marrow Culture 
Long term bone marrow culture (LTBMC) was performed as described pre-
viously (11). Briefly, confluent layers of the FBMD-l stromal cell line in 
25cm' flasks were overlaid with either 105 unseparated AML cells or 105 
CD34- cells or 10' CD34+ cells per flask. The cells were cultured in -modi-
fied Dulbecco's modified Eagle medium (DMEM, Gibco, Breda, The Ne-
therlands) supplemented with HEPES (3.5mM) (Sigma, St Louis, MO, 
USA), glutamine (2mM), sodium-selenite (lO-'M), ~-mercaptoethanol (10-
4M), 12.5% FCS, 12.5% horse serum (HS) and hydrocortisone 21-hemi-
succinate (lO-'M final concentration), in the presence of IL-3 (lOng/ml) and 
G-CSF (20ng/ml). IL-3 (10ng/ml) and G-CSF (20ng/ml) were added weekly 
to the cultures. Flask cultures of each fractiou and of the unfractionated 
AML were set up in triplicate and maintained at 33° C for 50 or 63 days 
with weekly half-medium changes and therefore removal of only half of the 
non-adherent (NA) cells. The output of NA cells and CFU-AML output of 
individual flasks was determined every two weeks. 
Cobblestone-Area-Fol'll1ing Cell Assayl 
The cobblestone area forming cell (CAFC) assay was performed as pre-
viously described (11). Briefly, confluent stromal layers of FMBD-l cells in 
96-wells plates were overlaid with isolated CD34+, CD34- or the unse-
58 
para ted AML cells in a limiting dilution setup. The medium was the same 
as used for LTBMC. Input values were 2854 nucleated cells (NC) per well 
for unseparated and CD34- cells and 28664 nclwell for CD34+ cells. Twel-
ve dilutions two-fold apart were used for each sample with 15 replicate 
wells per dilution. The percentage of wells with at least one phase-dark 
hematopoietic clone of at least five cells (Cobblestone area, CAl beneath the 
stromal layer was determined about every 14 days and CAFC frequencies 
were calculated using Poisson statistics as described (19,20). 
RESULTS 
AML growth il1 SCID mice 
Results of SCID mouse transplantations were obtained in 4 separate expe-
riments using different graft sizes. Transplantation of 7.5 x 10' of unsepa-
rated AML cells, the CD34+ or the CD34- fraction resulted in reproducible 
AML outgrowth as of day 35 (Table 1). The CD34- fraction, as well as un-
separated AML cells and the CD34+ fraction maintained AML growth in 
SCID mice during the latter period. Transplantation of lxl0' AML cells 
resulted in reproducible outgrowth of AML between days 55 and 106, 
while earlier AML outgrowth was mainly below the level of detection 
(Table 1). 
Graft failures were defined as a percentage of AML cells in the SCID mouse 
bone marrow smaller than 1 %. Three graft failures occurred between days 
55 and 10' among 42 transplanted mice: i.e. in two instances among mice 
transplanted with unseparated AML and in one recipient of the CD34- frac-
tion. These three mice had each received a graft of lxl0' cells. The mice 
were not evaluated at time points later than day 106. 
I Table I 
Time of % AML cells in BM (±SEM)" 
Evaluation Graft Size 
(xl0')/mouse CD34- CD34+ Unseparated 
Fraction Fraction AML 
35-45 7.5 20±9 38±14 20±11 
1 0' 23±23' 6±4' 
55-106 7.5 29±16 34±12 68±20' 
1 24±9 20±4 9±3 
Table I The percentages of huAML cells were determined on FACS scan analysis. 
BM: bone marrow. SEM: Standard Error of the Mean. ,. Graft failures included as 0%. 
59 
Retransplantation of BM recovered from recipients of 30 x 10' CD34- cells 
on day 28 resulted in regrowth of AML in two secondary recipients. The 
secondary grafts contained 4.0 x 10' and 4.6 x 10' AML cells. Following 
transplantation of the latter secondary recipients bone marrow infiltration 
by AML cells was 1 % at day 54 and 28% at day 95, respectively. 
A cell dose titration ranging from 0.33 x 10' to 30 xl0' of unseparated 
AML cells showed a dose effect relationship between cell dose and engraft-
ment of AML (Table 2). Outgrowth of AML was not observed after trans-
plantation of 9 x 104 CD34+ cells (data not shown). 
Flow cytometry 
Expression of CD34 and CD38 of unseparated AML cells before trans-
plantation is shown in Fig 2A. The AML cells were positive for CD33, 
CD45, HLA-Dr CD13 and CD15. Expression of CD34 and CD38 was ana-
lyzed in the bone marrow of all mice described. Irrespective of the initial 
graft, AML cells recovered from the bone marrow of SCID mice were 
CD34- and stained homogeneously for CD38 (Fig 2B). The CD34+ 
ICD38- cells had converted to a CD34-ICD38+ phenotype following growth 
in the SCID mouse. Bone marrow cells containing more than 10% human 
cells were used for more extensive analysis with CD13, CD15, CD33, 
CD34, CD38, CD45 and HLA-DR. The latter analysis was performed on 
the bone marrow of 22 mice, that had received an unseparated graft (n=8), 
a CD34+ graft (n=6) or a CD34- graft (n=6). Similar to the originally graf-
ted AML cells CD45+ cells were also positive for CD33 and HLA-DR, 
most cells were positive for CD13 and CD15. The light scatter properties of 
the AML cells had not changed: a homogeneous population of cells with 
light scatter properties confined to the blast region. 
No. of Mice Engraftedltransplanted 
CD34- CD34+ Unseparated 
Fraction Fraction AML 
4/5 6/8 5/5 
012 1/4 2/3 
4/4 6/6 212 
11/12 9/9 7/9 
Graft faillires were defined as <1 % AML cells in the bOl1e marrow . 
• vailies calclilated all the basis of data from less than fOllr e!lgrafted mice. 
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Flow cytometry did not reveal differences between AML cells recovered 
from mice transplanted with the CD34- fraction, the CD34+ fraction or 
unseparated AML cells. 
Table II 
Cell dose titration of tlnseparated AML cells transplanted into SCID mice 
Cell dose days %AML cells 
cells after mouse 
(x 10' ) transplant BM 
30 35 8 
35 91 
35 79 
35 37 
10 35 28 
35 60 
35 6 
3.3 35 3 
35 9 
1 
Table II 
44 2 AML cell proliferatioll ill the 
64 19 bOlle marrolV of SCID mice 
64 3 trallsplallted with graded 
0.3 81 1 doses of llllseparated AML cells, ill one experiment. 
81 0 Each percelltage represellts 
81 0 olle SCID mOllse. 
Morphological evaluation of cytospin preparations 
The bone marrow of 12 mice was analyzed for morphology, 4 transplanted 
with unseparated AML cells, 4 transplanted with the CD34+ fraction and 
4 transplanted with the CD34- fraction. In addition the bone marrow of one 
secondary recipient in the retransplantation experiment was analyzed. In all 
cases human cells in ScrD recipients with AML growth appeared as large 
mononuclear cells with a large nucleus containing one or two nucleoli 
among normal mouse BM cells. The scant cytoplasm contained a limited 
number of azurophilic granulae. The large cells were absent from normal 
mouse BM and the morphology was similar to the initial patient sample. 
Morphological differences were not apparent between AML cells recovered 
from mice transplanted with the CD34+ fraction, the CD34- fraction or 
unseparated AML. 
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Fig 1 Preparation of CD34+ and CD34- fractions 
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Fig 1 
Dot plot of forward light scatter vs. CD34 PE fil/orescellse illtellsity of 1/1Iseparated 
AML cells (Ia), alld the CD34+ (Ib) alld CD34- (Ic) fractiolls of AML after cell se[}ara-
tioll /lsillg DYllal beads. 
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Table III AML-CFU in CD34 positive and CD34 negative cell fractions 
AML-CFU per 105 cells 
AML unsepara ted CD34- fraction C34+ fraction 
Growth factor 
added 
none 0 0 0 0 0 0 
GM-CSF 0 0 0 0 0 0 
GM-CSF + IL-3 858 630 923 628 0 0 
IL-3 559 526 819 631 0 0 
SCF + IL-3 
+ GM-CSF 1014 793 1066 774 10 0 
Table III AML cololl)' (AML-CFU) formation of IIl1se/Jarated AML cells, the CD34-
fractioll or the CD34+ fractioll in the presence of the indicated hematopoetic growth 
factors. The data lVere collected from tlVO se/Jarate eX/JerimeJlts. 
Colony culture assay of AML cell fractions 
Almost all AML-CFU were recovered in the CD34- fraction and minimal 
numbers the CD34+ fraction (Table 3). Cultures were performed with 
fractions obtained in two separate experiments. No colonies were formed in 
the absence of growth factors. Uptake of tritiated thymidine in serum free 
culture (21) was not activated in the absence of growth factors (data not 
shown). 
Colony culture assay of AML cells recovered from SCID recipients 
The bone marrow of the SCID mice was obtained at variable times after 
transplantation and inoculated in a colony assay to assess numbers of AML-
CFU. AML-CFU were recovered from the SCID mice following transplan-
tation until as late as day 106 (Table 4). AML-CFU were derived from the 
bone marrow of these recipients of unseparated AML cells, the CD34+ as 
well as the CD34- fraction. Colony formation was not apparent in cultures 
without growth factors. 
Long Term Bone Marrow Culture (LTBMC) 
CD34- cells in the LTBMC flasks produced many non-adherent cells and 
AML-CFU (Fig 3a and 3b). In contrast, very low numbers of AML-CFU and 
NC were produced by CD34+ cells. AML-CFU or nucleated cell production 
by the CD34- fraction or unseparated AML cells did not decline for the 
duration of the assay. 
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Dot plots of CD34-FITC fluorescellce vs. CD38-PE fluorescellce of IIIlseparated AML 
cells (JIA) alld of imlllall AML cells recovered from SCID mouse bOlle marrow of a 
1II00Ise that had received a CD34+ graft (JIB). Humall AML cells ill pallel A colltailled 
more than 90% of the 1II0use BM as determilled all CD33-FITC/CD45-PE stailled sam-
ple. Panel A was used as a willdow for fluorescellce activated cell sorting. 
Table N AML colon)' formation of cells recovered fl'Ol11 SCID mice. 
TRANSPLANT 
(AML-CFU per 10' human cells) 
AML unseDarated CD34- fraction C34+ fraction 
Days after 
transplantation 
0 793 774 0 
35 132 
85 4 6 
37 
5 
106 2 173 61 
78 126 
Table N AML colony (AML-CFU) per 10' h'lll,m, cells formatioll ill a short term colo-
II)' assay of AML cells recovered frolll lIIice that had initially beell trallsplallted with 
III/separated AML cells, the CD34- fractioll or the CD34+ fractioll ill the presellce of 
fL-3, GM-CSF alld SCF. The IIIlIIlber of colonies is expressed perl 0' sorted humall 
AML cells. Colollies were 1I0t observed ill the absellce of growth factors or ill BM of 
IlIItransplmlted mice (data no/ showlI). 
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Cobblestone area forming cell frequencies of unseparated AML cells and 
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Cobblestone Area Forming Cell assay (CAFC assay) 
Frequency analysis of early and late CAs produced by the CD34- fraction, 
the CD34+ fraction or unseparated AML cells (Fig 4) revealed that nearly 
all early CAs were produced by the CD34- fraction. The CD34+ fraction 
produced 25 day 12 CAs/10' input NC (SEM 3.5), unseparated AML cells 
produced 303 day 12 CAs (SEM 44,7), 25% of unseparated AML cells were 
CD34+. Thus, 98% of early CAs of unseparated AML cells were produced 
by the CD34- fraction. Howevel; late CAs appeared in similar frequencies 
following seeding of both fractions in culture. CAs from the CD34- and 
CD34+ fraction were maintained until at least day 56. 
DISCUSSION 
Here we present an analysis of the progenitor cell compartment of a single 
case of human AML employing a variety of progenitor cell assays. Data 
from the SCID mouse model show that the CD34- fraction of AML cells 
had the same capacity to initiate and maintain long term growth of AML in 
vivo as had the CD34+ fraction. The CD34-fraction was capable of maintai-
ning AML growth for more than three months and was also able to initia-
te renewed proliferation of AML after transfer to a second recipient. 
The outgrowth of AML following transplantation of CD34- grafts cannot 
be attributed to contaminating CD34 positive cells. The cell dose titration 
revealed that more than 0.3 x 10' of unseparated ruVlL cells (i.e. more than 
8 x 104 CD34+ cells) are required to obtain measurable AML growth. For 
extensive bone marrow infiltration (>20%) at day 35 more than 3.3 x 10' 
of unseparated AML cells (i.e. more than 83 x 104 CD34+ cells) are requi-
red (Table 2). Contamination of CD34- grafts by CD34+ cells was far below 
these levels, as the CD34- fractions were 98% pure. 
The leukemic origin of the cells expanding in the SCID mice was confirmed 
by morphologic examination and by the leukemic immunophenotype. In 
addition, proliferation of human hematopoietic cells was observed in the 
absence of exogenous hematopoetic growth factors. Under these circum-
stances normal bone marrow does not expand in SCrD mice (22). 
Other investigators have reported one case of AML in which long term 
growth capacity was restricted to the CD34+/CD38- fraction (10). In the 
latter case the immunophenotype of the repopulating AML cells was iden-
tical to that of the fraction of normal bone marrow that contains 
hematopoietic stem cells. Howevel; our data demonstrate that the expres-
sion of CD34 and long-term leukemia initiating capacity do not necessarily 
correlate and can be separated as independent characteristics of AML pro-
genitors. The difference between these and previously published data is pro-
bably due to cellular heterogeneity of AML. This heterogeneity may beco-
me apparent when additional cases of AML are examined. As yet only few 
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cases of AML have been investigated as regards the distribution of AML cells 
with long term capacity over phenotypically defined AML compartments. 
Cases of AML proliferating in ScrD mice without exogenous growth factor 
supply have been described by others (10,23). AML cells recovered from the 
SCID mice had retained an absolute dependence on hematopoietic growth 
factors as regards the colony forming abilities in vitro. Therefore there was 
no in vivo selection of an AML subclone in the SCID mice that is indepen-
dent on IL-3. Interaction with the bone marrow microenvironment or sti-
mulation by mouse cytokines offer more likely explanations for the prolif-
erative outgrowth of AML in SCID recipients. 
In contrast to the similarities between the CD34+ and the CD34- fractions 
with respect to in vivo growth, clear differences were demonstrated in 
vitro. AML-CFU were almost entirely contained in the CD34- fraction 
(Table 3). Both the CD34+ and the CD34- fractions initiated long term 
growth. Consistently, early CA production, an index of late progenitors, 
was mainly seen following seeding of CD34 negative cells in the CAFC 
assay. Thus, the presence of AML-CFU or early CAFC in a particular frac-
tion of AML cells does not predict for long term growth of AML. Similarly, 
the production of NC and AML-CFU in LTBMC was mainly observed in 
the CD34- fraction (Fig. 3). The latter two parameters therefore do not cor-
relate with long term growth of AML either. 
The only in vitro property shared by the CD34+ and CD34- fractions was 
the presence of late CAFCs (Fig 4). In normal hematopoiesis late CAFCs are 
generally regarded as more primitive normal hematopoietic cells. Using chi-
meric mouse models, late CAFCs (week 4-8) have been shown to be corre-
late with normal stem cells that induce stable multi-lineage chimerism in 
vivo. In contrast early CAFC (day 10) frequencies accurately reflect those of 
day 10 spleen colony-forming cells, which express transient repopulating 
ability in mice (24). For human hematopoiesis, it has been demonstrated 
that late CAFCs are predominantly contained in the CD34+, Rhodami-
ne123dull, HLA-DRlow fraction which is in agreement with previously 
reported long term culture initiating cell characteristics (11). Similar to the 
.late CAFCs of normal hematopoiesis, late CAFCs of the case of AML inves-
tigated here, are cells with long term growth capacity. This was demonstra-
ted by the long term growth of leukemic late CAFCs in vitro in the CAFC 
assay and confirmed by the long term growth of both fractions containing 
late CAFCs in scm mice. Since other clonogenic assays (AML-CFU, 
LTBMC, early CAFC formation in the CAFC assay) failed to correlate with 
long term growth capacity in vivo, we conclude that the late appearing 
CAFC is a highly immature cell observed in vitro in this case of AML. 
The capacity to induce long term growth is generally accepted as the para-
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meter of choice for immaturity. The CD34+ and CD34- fractions both con-
tained these immature subsets. This is not observed in normal bone marrow 
and may be a phenomenon that characterizes the maturation abnormality 
of this case of AML. Only CD34- cells were recovered from SCID mice 
transplanted with the CD34+ or CD34- fractions, indicating that the 
CD34+ and CD34- precursors both generated CD34- progeny. It should be 
noted that more mature progenitor cells such as AML-CFU and early 
CAFCs were observed in the CD34- fraction only. This indicates that the 
majority of more mature progenitor cells becomes CD34 negative. 
In some cases normal bone marrow cells overgrow leukemic cells in LTBMC 
(25,26). The CD34+ fraction of this case of AML could have contained 
normal CD34+ precursors. However, these normal precursors would have 
produced CFU-GM and NCs at 4 weeks of culture (23). 
Thus, both CD34- and CD34+ subsets of this AML sample contained 
immature progenitors with the capadty to initiate long term AML growth 
as identified in vivo as well as in vitro, indicating asynchrony between func-
tional and immunophenotypical maturation of AML progenitor cell com-
partments. The capacity of AML subpopulations to initiate and maintain 
leukemia in vivo cannot be determined on the basis of the expression of 
CD34 or the production of AML-CFU. 
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ABSTRACT 
A subset of leukemic cells is assumed to maiutain long-term growth of acute 
myeloid leukemia (AML) in vivo. Characterization of these AML progeni-
tor cells may further define growth properties of human leukemia. 
In vitro incubations with 5-fluorouracil (5-FU) have been used for enrich-
ment of normal primitive hematopoietic stem cells. By analogy to normal 
hematopoiesis it was hypothesized that primitive leukemic stem cells might 
be kinetically more inactive than colony forming cells (AML-CFU). To exa-
mine this hypothesis, conditions were established for incubation with 5-FU 
that eliminated all AML-CFU. These conditions selected a 5-FU resistant 
AML fraction that was evaluated for its capacity for long-term growth by 
transplantation into mice with severe combined immuno-deficiency (SCID) 
and long-term culture in the quantitative cobblestone area forming cell 
(CAFe) assay. 
Transplantation of the 5-FU resistant fraction of four cases of AML into 
SCID mice resulted in growth of AML. Whereas no AML-CFU survived, 
31-82% of primitive (week 6) CAFC were recovered from the 5-FU treated 
cells. Hematopoietic cells proliferating in the CAFC assay were shown to 
be leukemic by cytological, cytogenetic or molecular analysis. The reduction 
of AML growth as determined by outgrowth of AML in SCID mice was in 
the same order of magnitude as the primitive (week 6) CAFC reduction. 
This indicates that both assays measure closely related cell populations and 
it that the CAFC assay can be used to study long-term growth of AML. 
These res nits demonstrate a hierarchy of AML cells that includes 5-FU resi-
stant progenitors. These cells are characterized as primitive (week 6) CAFC 
and as lenkemia initiating cells in SCID mice. 
INTRODUCTION 
It is currently assumed that a subset of leukemic cells maintains long-term 
growth of acute myeloid leukemia (AML) in vivo. Investigation of this sub-
set may be useful for understanding outgrowth and relapse of AML. This 
would require the isolation and functional characterization of the subpopu-
lation of leukemic cells with the capacity to maintain AML. (1) 
Isolation of precursors from normal bone marrow has required the combi-
nation of functional assays and purification strategies. One particular puri-
fication strategy is based on incubation with 5-f1uorouracil (5-FU). 5-FU is 
toxic to cells in S-phase and this antimetabolite interferes with mRNA spli-
cing in metabolically active cells. (2) 5-FU resistance is a property of muri-
ne hematopoietic cells with long-term in vivo repopulating abilities (LTRA) 
and long-term abilities in vitro, indicating that these cells are mainly in a 
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kinetically quiescent state (GO-phase). (3-7) Early human hematopoietic 
progenitors showed similar resistance to 5-FU. (8-10) Prolonged incubation 
of unseparated human hematopoietic cells with 5-FU selects for quiescent 
pluripotent cells with an immature phenotype. (11) 
For identification of AML progenitors c1onogenic assays in semi-solid 
media have been used. This resulted in identification of the AML colony for-
ming unit (AML-CFU). Thymidine suicide studies showed that a high pro-
portion of AML-CFU are synthesizing DNA. (12) It is likely that AML-CFU 
may be eliminated by concentrations of 5-FU, that allow for the survival of 
quiescent subsets of primitive leukemic cells as is the case in normal hema-
topoiesis. 
We sought to identify AML cells resistant to 5-FU. In analogy to normal 
bone marrow such AML cells may constitute a primitive subset of AML, 
that is enriched for AML cells with long-term growth abilities. We selected 
conditions for incubation with 5-FU that eliminated all AML-CFU. The 
capacity of the 5-FU resistant AML fraction to initiate leukemia in vivo was 
investigated by transplantation into mice with a severe combined immuno-
deficiency (SCID). In addition, the long-term in vitro abilities were investi-
gated in the cobblestone area forming cell assay (CAFC assay), a limiting-
dilution type long-term culture system for hematopoietic progenitor cells. 
(7,8,13,14) 
MATERIALS AND METHODS 
Acute myeloid leukemia cells 
Peripheral blood (PB) samples were obtained following informed consent 
from four patients presenting with AML diagnosed according to the criteria 
of the French-American-British Committee (tAB). (15) AML cases were 
selected for their abilities to proliferate in SCID mice and the presence of a 
leukemia specific marker. AML #1 had a normal karyogram. The leukemic 
growth characteristics in the CAFC assay and SCID mice of AML #1 have 
been described before. (16) AML case #2 showed 47XX,+8, del7(q22-q36) 
as the cytogenetic markers. AML #3 had normal cytogenetics but carried a 
point mutation in the G-CSF receptor (G-CSF-R) gene. (17) AML #4 had a 
translocation (9;22) (Table 1). Nucleated cells were isolated as a buffy 
coat. The cells were cryopreserved in 10 % dimethylsulfoxide, 20% heat-
inactivated fetal calf serum (FCS) and Iscove's modified Dulbecco's medium 
(IMDM, Gibco, Breda, The Netherlands). After thawing by stepwise diluti-
on (18), the viability as assessed by trypan blue staining ranged from 72-
92%. 
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Incubation of AML cells with 5-F1uorouracil 
5-Fluorouracil (5-FU; Sigma, St Louis, MO, USA) was dissolved in phosp-
hate buffered saline (PBS). AML cells (2xl0'/L) were incubated in 175 cm' 
polystyrene tissue culture flasks (Becton Dickinson, NJ) in IMDM (Gibco) 
and 10% FCS with 5-FU at 0,15,25,40 and 80pg/mL for 24 hours at 37'C 
in an atmosphere of humidified 5% C02. Equivalent proportions of the 
flasks based on input values were used in the various assays (CFU-AML, 
CAFC, SCID mouse transplantations), without corrections for cell loss or 
viability in order to assess true variations in the recovery of specific subsets 
of cells. 
Serum free colon), culture assa), 
Cells (the equivalent of 4x 104 input cells) were plated in 35-mm dishes 
(Becton Dickinson, San Jose, CA, USA) in lmL IMDM (Gibco) containing 
0.9% methylcellulose, 1.5% bovine serum albumin (BSA, Sigma, St Louis, 
MO), insulin (0.025U/mL), linoleic acid (2.8pg/mL), cholesterol 
(7.8pg/mL), sodium selenite (0.18ng/mL), ~-mercaptoethanol (3.5pl/mL), 
and human transferrin (0.62mg/ mL). Assays were performed in triplicate 
in the presence of granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Behringwerke AG, Marburg, Germany, 5ng/mL), interleukin-3 (IL-3) 
(Sandoz BV, Basel, Switzerland, 10ng/mL) and stern-cell factor (SCF) (Im-
munex, Seattle, WA 200ng/mL). Colonies were scored after 14 days of 
incubation at 37°C in a humidified atmosfere and 5% C02 . 
SCID mice and transplantation of AML 
Female specific pathogen-free CB17 scid/scid mice (5-8 weeks of age) were 
purchased (Harlan CPB, Austerlitz, The Netherlands) and housed under 
specific pathogen-free conditions in a laminar air flow unit. The mice were 
supplied with sterile food and acidified drinking water with 100mg/L 
ciprofloxacine (Bayer AG, Leverkusen, Germany). The plasma Ig level of 
these mice was determined with an ELISA using a sheep anti-mouse antibo-
dy reacting with mouse IgG and IgM (Boehringer Mannheim Biochemica, 
Penzberg, Germany) and animals with plasma Ig levels over 40pg/ml were 
excluded. To enhance outgrowth of human hematopoietic cells in vivo 
macrophage depletion was performed with the use 0.2mL Cl2MDP liposo-
mes intravenously on the day before transplantation as described. (19-21) 
Total body irradiation (TBI) at 3.5Gy (dose rate: 0.95Gy/minute) was deli-
vered by a J37Cs source (Gammacell, Atomic Energy of Canada, Ottawa, 
Canada) adapted for the irradiation of mice. The graft size was the equiva-
lent of 1 Oxl 0' AML input cells for AML #1 and #2, the equivalent of 
20xl0' AML input cells for AML #3 and the equivalent of 30xl0' AML 
input cells for AML #4. The transplants, suspended in 300pL Hanks balan-
ced salt solution (HBSS) (Gibco, Breda, The Netherlands) and 0.1 %BSA 
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(Sigma), were injected intravenously (iv) into a lateral tail vein. The first two 
cases of AML had been shown to proliferate in SCID mice without support 
of human hematopoietic growth factors and AML#3 and #4 were IL-3 
dependent. The latter SCID mice received 60rg of human IL-3 (Gist 
Brocades, Delft, The Netherlands) in 200pL HBSS and 1 %BSA (Sigma) int-
raperitoneally, five days a week as described. (22) 
Tissue collections 
SCID mice were sacrificed by C02 inhalation followed by cervical disloca-
tion in accordance with institutional animal research regulations. Cell sus-
pensions were prepared from the bone marrow (BM) of both femora and 
used for flow cytometry and the preparation of cytospin slides. Cytospin 
slides were stained with May-GrUnwald Giemsa and morphology was mi-
croscopically evaluated. 
Flow Cytometry 
The initial leukemias and BM samples from mice that had been transplan-
ted with leukemic grafts were stained or double-stained with the following 
mouse monoclonal antibodies: CD34-FITC, CD34-PE, CD3S-PE, CD34-
FITClIgGI-PE, CD34-FITCICD3S-PE, CD34-FITCIHLA-DR-PE, CD34-
FITC/c-kit-PE, CD34-FITCICD33-PE and finally CD45-FITCICD33-PE. 
Mouse IgGI-FITC and mouse IgGI-PE conjugated antibodies and samples 
from non-transplanted SCID mice were used as controls. The antibodies 
were obtained from Becton Dickinson, San Jose, CA, USA. Fluorescence 
was measured using a FACSCAN flow cytometer and Lysis II software 
(Becton Dickinson, Immunocytometry Systems). Erythrocytes and dead cells 
were excluded from analysis by gating on forward and orthogonal light 
scatter. To determine the percentage of human cells in the mouse bone mar-
row cells staining with at least two different antibodies for human hemato-
poietic cells were counted as human cells. (23) 
Fluorescent in situ hybridization (FISH) for detection of trisomy 8 
We used FISH for detection of trisomy S in interphase nuclei of cells of 
AML #2 following transplantation in SCID mice and proliferation in the 
CAFC assay. The DNA probe was specific for the a-satellite sequences on 
the centromeric region of chromosome S (DSZ2). (24) Following denatura-
tion and hybridization procedures the hybridized probe was detected using 
fluorescein isothiocyanate (FITC) labeled avidin (Vector Laboratories, 
Burlingame, CAl. Nuclei were counterstained with propidium iodide 
(Sigma, St. Louis, Mo). The slides were analysed employing a fluorescense 
microscope (standard 14 IV FL Zeiss) equipped with a (FITC) filter combi-
nation 09 (BP 450-490, FT510, LP520; Zeiss). (25) 
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Table 1 Characteristics of the analyzed cases of AML 
AML FAB Leukemic marker':- IL-3 dependent 
Classification in scm mice' 
#1 M2 none no 
#2 M1 +8, del7(q22-36) no 
#3 M1 R-G-CSF gene mutation yes 
#4 M4 t(9;22) yes 
'-Lellkemic marker indicates a lellkemia-specific characteristic of the AML described. 
'IL-3 dependent indicates that for extensive AML proliferation in vivo SCID mice have 
to be injected with human IL-3 (60,lg intraperitoneally, 5 days a week). 
':>90% of the AML cells staining with a specific antibody as determined by {low 
Detection of G-CSF receptor gene mutation 
AML #3 is characterized by the presence of a point mutation in the G-CSF 
receptor (G-CSF-R) gene resulting in an aberrant G-CSF-R isoform, unique 
to this case of AML. (17) PCR of the G-CSF-R gene was performed as 
described with the forward primer FWI16 5'-ACCCTTTGTGTTCCAC-
CAGT-3' (in intron 16) and GR RVl 3'-GGTATTCGGGTACTGATTCTA-
GATG-5' (nucleotide 2745-2769) followed by digestion with Kpn1, which 
selectively degrades the PCR product of the mutated G-CSF receptor gene. 
Cobblestone-Area-Forming Cell Assay 
The cobblestone area forming cell (CAFC) assay was performed as des-
cribed.(8) Briefly, confluent stromal layers of FMBD-l cells in 96-wells pla-
tes were overlaid with AML cells in a limiting dilution method. The cells 
were cultured in IMDM supplemented with 20% of a selected horse serum 
(HS) batch and hydrocortisone 21-hemisuccinate (10-'M final concentrati-
on). IL-3 (12.5nglmL) and G-CSF (20nglmL) were added weekly to the cul-
tures. Input values were the equivalent of 50.000 nucleated cells (NC) per 
well. Twelve dilutions two-fold apart were used for each sample with 15 
replicate wells per dilution. The percentages of wells showing at least one 
phase-dark hematopoietic clone of at least five cells (Cobblestone area, CAl 
beneath the stromal layer were determined at 2 week intervals and CAFC 
frequencies were calculated using Poisson statistics as described.(13) 
In normal hematopoiesis stroma dependent clones that are observed late in 
culture are indicators of primitive long-term repopulating stem cells in vivo, 
while early appearing clones are tentative indictators of transiently repopu-
lating progenitors.(7,8) At intervals the content of some wells was harves-
ted for additional investigation. 
Immunophenotype' (percentage of positive cells) 
CD34 CD38 HLA-DR c-kit CD33 CD45 
24% 50% + + + 
+ 30% + + 
25% + + + + + 
40% + + + + 
cytometry and compared to a IgGI-FITC or IgGIPE control. 
- :<10% of the AML cells staining with a specific antibody as determined by flow 
Abbreviations: FAB: French-American-British, R-G-CSF: G-CSF rece/Jtor 
cytometry alld compared to a IgGI-FITC or IgGIPE cOlltrol. 
RESULTS 
Elimination of AML-CFU by exposure to 5-FU 
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To determine a concentration of 5-FU eliminating all CFU-AML a dose tit-
ration ranging from 0-80pg/mL of 5-FU was carried out. A 24 hours incu-
bation at a concentration of 25pg/mL of 5-FU reduced the number of 
AML-CFU to less than 2% as compared to the colony numbers in the 
absence of 5-FU in all cases of AML tested (data not shown). A higher con-
centration of 40 pg/mL of 5-FU eliminated all CFU-AML (Table 2). AML 
cell viability varied from 50% to 80% in 5-FU containing cultures, which 
compared to 65% to 80 % viability for control incubations without 5-FU. 
This indicated that most cells sensitive to 5-FU had not been killed within 
24 hours. In subsequent experiments (SCID mouse transplantations, CAFC 
assay) AML cells were incubated at 40pg/mL of 5-FU to examine the 5-FU 
resistant fraction. 
Outgrowth of AML in SCID mice 
The 5-FU resistant fractions of AML cases #1 thl'll #4 were transplanted 
into SCID mice in individual experiments. Groups of 3-5 SCID mice were 
killed at 35 to 47 days after transplantation. Whereas the 5-FU resistant 
fractions of AML did not contain measurable numbers of AML-CFU, in all 
instances these fractions had the capacity to initiate leukemia in SCID mice 
(Table 2). The levels of AML infiltration by the 5-FU resistant fraction in 
the marrow of SCID recipients were less than those of control transplanta-
tions. By comparison of these values of infiltration and those in a cell dose 
titration of two cases of AML the 5-FU fraction appeared to be equivalent 
to an approximate threefold reduction of the unseparated graft (Table 3). 
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Table II Growth characteristics of 5-FU exposed and control AML cell 
AML AML cell population':' % AML mOllse EM ±SD' AML-CFU 
case (n of mice) (/10') 
1 untreated 91±5 (5) 2461 
5-FU exposed 44±21 (5) 0 
5 -FU resistant (%)' 0 
2 untreated 19±18 (5) 4 
5-FU exposed 9±15 (5) 0 
5 -FU resistant (%) 0 
3 untreated 63±17 (4) 71 
5-FU exposed 20±6 (4) 0 
5 -FU resistant (%) 0 
4 untreated 10±13 (3) 271 
5-FU exposed 3±5 (3 ) 0 
5 -FU resistant (%) 0 
Human AML cells proliferate in the SCID mouse bone marrow 
Cells recovered from the SCID mouse bone marrow were characterized as 
AML cells. Flow cytometry was performed with the same panel of mono-
clonal antibodies as was used for the initial immunophenotyping of the 
graft. It was shown that the immunophenotypes of cells recovered from the 
SCID mOllse bone marrow were identical to the AML immunophenotypes 
of the respective grafts with the following exceptions: CD34 positivelCD38 
negative cells from AML case #1 had converted to a CD34 negativelCD38 
positive phenotype as described earlier(16) and CD34 positive cells from 
case #3 had converted to a CD34 negative phenotype. Cytospin slides pre-
pared from the bone marrow of mice transplanted with AML #1 thru #4 
revealed evident blast cells. The morphological identification of leukemic 
blasts was relatively easy due to the considerably larger size of AML blasts 
as compared to normal mouse EM cells. The percentages of AML blasts 
counted on the cytospin slides were similar to those determined by flow-
cytometry (data not shown). FISH performed on bone marrow cells prolif-
erating in SCID mice transplanted with AML #2 confirmed the trisomy 8 
in the bone marrow of all 3 mice examined. More than 90% of the cells stai-
ning with an anti-centromere probe for chromosome 8 (human cells) 
showed 3 fluorescent dots. 
Cobblestone area forming cell assay (CAFe assay) 
In parallel to the SCID mouse transplantations long-term growth of the 5-
populations in SCID mice and ill vitro 
week 2 CAFC week 6 CAFC 
(l10'±SEM) (l10'±SEM) 
10±4 132±28 
1.7±0.5 52±8 
17 39 
1.9±0.5 11±3.4 
<0.2'" 3.4±1.0 
<11 31 
6.2±1 5.2±1.46 
0.9±0.4 3.1±1.13 
15 60 
38±0.4 3.8±0.6 
1.6±0.4 3.1±0.6 
4 82 
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Table II: # AML cells were illcubated 
for 24 hours ill IMDM alld 10% FCS, 
with or without 40/lg/ml of 5-FU. The 
percelltage of humall cells proliferatillg 
ill the SCID mOllse bone marrow was 
determilled by (low-cytometry # The 
percelltage of 5-FU resis/allt CFU-
AML, week 2 CAFC alld primitive 
week 6 CAFC were derived from the 
quotiellt of the vailles of the 5-FU 
exposed fractioll alld IIlItreated AML 
cells. ". vallie below the detectioll limit 
of the assay. 
Abbreviations: BM: bone marrow, 11: 
lIumber of mice ill experiment, SD: 
stalldard deviatioll, SEM: stalldard 
error of the meall, CFU-AML: colollY 
formillg IIlIit AML, CAFC: cobblestolle 
area forming cell. 
FU resistant fractions was investigated in the quantitative long-term bone 
marrow culture system, i.e. the CAFC assay. Frequency analysis of hemato-
poietic precursor cells in vitro showed in the number of week 2 CAFC in the 
5-FU-exposed fraction a reduction towards 4-17% of the unexposed AML 
cells among the four AML specimens examined. In contrast, more primiti-
ve (week 6) CAFC were reduced to 31-82% only. 
After 6-10 weeks of culture, cells were recovered from a series of wells used 
for the CAFC assay and cytospin preparations were made. Morphological 
examination of the hematopoietic cells harvested from the CAFC assay of 
AML #1 revealed 92% blast cells among the hematopoietic cells prolifera-
ting in the CAFC assay, more mature myeloid cells were nearly absent. In a 
CAFC assay of normal peripheral blood stem cells always less than 15% 
myeloblasts were counted at week 6, and all morphological maturation sta-
ges of the neutrophil series were represented. FISH analysis of case #2 reve-
aled the trisomy 8 in 50% of the 52 evaluable cells staining with the anti-
centromere probe (Data not shown). Morphologically 75% of all hemato-
poietic cells in the CAFC assay were myeloblasts. In AML #3 cells harves-
ted from the CAFC assay the presence of the specific mutant G-CSF-R gene 
was demonstrated using PCR. (Figure 1). Morphological examination of the 
cells proliferating in the CAFC assay showed 83% myeloblasts. AML # 4 
cells were harvested from the CAFC assay, however contamination with 
yeast cells interfered with further investigation. 
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Table III Cell dose titration of AML cells transplanted into SCID mice 
Cell dose %AML cells mouse BM 
(X 10' per mouse) 
AML#l AML#2 
30 8 75 
91 90 
79 90 
37 
10 28 88 
60 61 
6 8 
3.3 3 13 
9 4 
1 2" 1 
19" 1 
3" 2 
0.3 1'" 
0'" 
0'" 
AML cell proliferatioll ill the bOlle marrolU of SCID mice trallsplanted with graded 
doses of AML cells, ill aile experilllellt. Each percelltage represellts aile SCID 1II01lse, 
evaillated all day 35. ,. evaillated betweell days 44-81. 
DISCUSSION 
We identified a subset of AML cells devoid of AML-CFU and resistant to 5-
FU. This subset initiates AML in scm mice and contains 31-82% of the 
AML cells with the ability to initiate long-term growth in the CAFC assay 
(Table 2). The 5-FU sensitive fraction of normal hematopoietic cells pro-
duces a high number of colony forming units (CFU-C) and week 2 CAFC in 
culture, whereas the 5-FU resistant subpopulation contains the great majo-
rity of primitive (week 6) CAFC (8) and primitive normal hematopoietic 
cells. (4-6,9-11) The cell population that we have identified here is enriched 
for immature leukemic precursors and shares these characteristics with its 
normal analogue. This cell population may be identical to or closely resem-
ble the leukemic stern cell population. These observations suggest a hierar-
chy of AML cells similar to that in normal hematopoiesis: a hierarchy from 
kinetically quiescent immature progenitors identified as primitive (week 6) 
0.40 
0.34 
0.30 
0.20 
m 1 2 3 4 5 
690 
483 
207 
79 
Figure 1 Presellce of a lellkemia specific poillt mlltatioll ill the G-CSF receptor gelle 
ill cells proliferatillg ill the CAFC assay of AML #3. 
Agarose gel electrophoresis of PCR fragments after KplII digestioll showillg a thawed 
sample of AML#3 (Ialle 1), 2 samples of the CAFC assay of AML #3 harvested after 5 
alld 7 weeks of cllitllre (Ialles 2 and alld 3 respectively). As COli trois a sample of the stro-
mal celllille FMBD-ll1sed for stromal cllltllre (Ialle 4) alld a sample of AML #2 (Ialle 
5) were illelllded. Abbreviatioll M: marker lalle (kb) 
CAFC and the cells initiating leukemia in SCID mice towards kinetically 
active mature progenitors such as week 2 CAFC and AML-CFU. 
The reduction of AML growth as determined by outgrowth of AML in 
SCID mice and by the number of week 6 leukemic CAFC was in the same 
order of magnitude. The hematopoietic cells proliferating in the CAFC 
assay could be shown to be leukemic by cytological, cytogenetic or molecu-
lar analysis, although the presence of some normal progenitors could not be 
fully excluded. These data indicate that both assays measure closely related 
cell populations and that the CAFC assay can be used for study of long-term 
growth of AML. The issue whether the differences observed between the 
percentage of 5-FU resistant week 6 CAFC and 5-FU resistant leukemia ini-
tiating cells in SCID mice are significant requires further investigation. 
AML-CFU phenotypes display considerable heterogeneity among patients. 
(26,27) Nevertheless, a generally more immature immunophenotype is 
expressed by AML-CFU as compared to the unseparated AML cell popula-
tion, and differentiation of AML-CFU in vitro has been observed. (26-30) 
AML-CFU recovered from methylcellulose cultures can be replated and pro-
duce secondary colonies.(l) The capacities for (limited) differentiation and 
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self renewal are consistent with the role of the AML-CFU as a progenitor 
cell. The data presented here show that the AML-CFU is a relatively matu-
re progenitor and functionally distinguishable from most cells initiating 
long-term growth of AML. However a definitive determination of any long-
term potential of AML-CFU would require isolation of this subset. 
Another approach towards the isolation of primitive leukemic progenitor 
cells is based on the immunophenotypical similarities between normal and 
leukemic progenitors. A fraction of normal bone marrow enriched for 
repopulating stem cells has been identified as CD34+, CD33-, CD38-, HLA 
DR-, Thy-1low, negative for specific lineage antigens and low in rhodami-
ne-123 uptake. (31-36) In AML a CD34+ICD38- fraction is present in 
approximately one third of the cases. (17) Cells initiating outgrowth of 
AML in immunocompromised mice were recovered exclusively from the 
CD34+ICD38- fraction in at least three cases of AML. (38,39) These data 
may not apply to each and every case of AML as we identified one case 
with identical abilities to initiate leukemia in scm mice of both the CD34+ 
and the CD34- fractions. (16) The heterogeneity of immunophenotype 
among cases of AML and the apparent lack of functional significance of 
expression of CD34 in AML may interfere with this approach to identify 
leukemic progenitors by immunophenotype. 
Our data indicate that selection of AML subsets based on functional char-
acteristics such as cytokinetic activity might offer a more generally applica-
ble approach to the investigation of leukemic progenitors. 
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ABSTRACT 
We studied the cell kill induced by GM-CSF fused to Diphtheria Toxin (DT-
GM-CSF) in acute myeloid leukemia (AML) samples and in populations of 
normal primitive hemopoietic progenitor cells. AML samples from three 
patients were incubated in vitro with 100 ng/ml DT-GM-CSF for 48 hours, 
and AML cell kill was determined in a proliferation assay, a c1onogenic 
assay (AML-CFU) and a quantitative long-term bone marrow culture i.e. 
the leukemic-cobblestone area forming cell assay (L-CAFC). To measure an 
effect on cells with in vivo leukemia initiating potential DT-GM-CSF expo-
sed AML cells were transplanted into immunodeficient mice. 
In two out of three samples it was shown that all AML subsets, including 
those with long term abilities in vivo (SCID mice) and in vitro (L-CAFC 
assay) were reduced in number by DT-GM-CSF. Cell kill induced by DT-
GM-CSF could be prevented by coincubation with an excess of GM-CSF, 
demonstrating that sensitivity to DT-GM-CSF is specifically mediated by 
the GM-CSF receptor (GM-CSFR). Therefore binding and internalization of 
GM-CSF probably occur in immature AML precursors of these two cases of 
AML. The third AML sample was not responsive to either GM-CSF or DT-
GM-CSF. 
The number of committed progenitors of normal bone marrow (BFU-E, 
CFU-GM and CAFC week 2) and also the number of cells with long term 
repopulating ability, assayed as week 6 CAFC, were unchanged after expos-
ure to DT-GM-CSF (100 ng/ml, 48 hours). These studies show that DT-
GM-CSF may be used to eliminate myeloid leukemic cells with long-term 
potential in vitro and in immunodeficient mice, whereas normal hemopoie-
tic stem cells are spared. 
INTRODUCTION 
Human acute myeloid leukemia (AML) cells generally express receptors for 
hemopoietic growth factors. The granulocyte-macrophage colony stimula-
ting factor receptor (GM-CSFR) is expressed as a heteromeric complex con-
taining an (J, and a p subunit [1,2). In AML this receptor is mostly of high 
affinity. The GM-CSFR of AML cells is functional, because cells from more 
than 80% of AML cases respond to GM-CSF with proliferation (1,3-5). 
Such receptors with a narrow tissue distribution and a high affinity are 
promising targets to selectively deliver toxins to malignant cells (6, 7). 
A truncated form of the potent Diphtheria toxin (DT) has been fused to a 
number of cytokines (8-12). It has been shown before that such fusion pro-
teins may be used for the elimination of malignant cells. The deleterious 
effects of DT-fusion proteins require receptor binding and subsequent inter-
85 
nalisation by receptor-mediated endocytosis. This is followed by processing 
of the DT into its active form and delivery of the NH2-domain associated 
ADP-ribosyltransferase to the cytoplasm. It kills the cell by catalyzing the 
irreversible ADP ribosylation and subsequent inactivation of elongation fac-
tor 2. The number of internalized DT molecules required for cell kill are 
quite low (13-16). 
Recently we established that DT-GM-CSF may be used to target primary 
human AML as determined in an in vitro proliferation assay (17). Limiting 
dilution experiments of AML cells in immunodeficient mice showed that the 
frequency of the cell with the ability to initiate leukemia in immunodeficient 
mice is low and varies between 0.2 and 100 per 106 AML cells (18). 
Whether these immature AML cells, with the ability to maintain AML in 
vivo, express functional GM-CSFR or respond to GM-CSF is unknown. 
Probably, the sensitivity of this AML subset determines the antileukemic 
efficacy of a therapeutic intervention. The immunodeficient mouse model is 
an established system for investigation of immature human AML cells (19-
21) and might serve as a useful tool to investigate the effect of DT-GM-CSF 
to AML cells with long term repopulating capacity. 
Applicability of DT-GM-CSF could be hampered by the toxic effect on nor-
mal hemopoietic cells. It has been shown that the GM-CSFR is probably not 
expressed by the phenotypically most immature subsets of CD34 positive 
cells (22), and GM-CSFR mRNA was not observed in 5-Fluorouracil resi-
stant bone marrow cells (23). This evidence suggests that normal hemo-
poietic stem cells may escape cell death induced by DT-GM-CSF. 
Here we report on the efficacy of DT-GM-CSF for elimination of AML cells 
with long-term repopulating abilities in vivo, using transplantation of DT-
GM-CSF exposed AML cells into scm mice. In addition we used the cob-
blestone area forming cell (L-CAFC) assay, a quantitative long-term bone 
marrow culture system that we have applied to the investigation of AML 
before (20, 24). The toxicity of DT-GM-CSF to normal hemopoietic cells 
under identical conditions was determined in the clonogenic assay for com-
mitted progenitors, and in the CAFC assay for hemopoietic stem cell subs-
ets (25). 
MATERIALS AND METHODS 
Human AML cells 
Samples were obtained, following informed consent, from untreated 
patients with AML. The cases were classified cytologically according to the 
criteria of the French-American-British Committee (FAB) (26). 
Mononuclear cells were isolated as a buffy coat, without T cell depletion 
and frozen using a controlled freezing apparatus followed by storage in 
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liquid nitrogen. After thawing by stepwise dilution, cell viability assessed by 
trypan blue staining ranged from 62 - 91 %. 
Incubations with DT-GM-CSF 
The construction and purification of DT-GM-CSF has previously been 
described (17). Normal bone marrow (nBJ\-1) cells from healthy donors and 
AML cells were exposed to DT-GM-CSF (100 ng/ml) in serum free medium 
(SFM) (27) at a density of 2.5 xl0' cells/ml at 3TC in a humidified 5% C02 
atmosphere for 48 hours. Control incubations in SFM without DT-GM-CSF 
and the incubation with a equimolar concentration of human GM-CSF 
(GM-CSF; a gift from Sandoz BV, Basel, Switzerland) were performed 
simultaneously. For competition experiments an excess of GM-CSF (2 
pg/ml) was added to the cultures containing DT-GM -CSF. 
Equivalent proportions of the flasks based on the input values were used in 
the assays. No correction for cell loss or viability was applied. 
3H-Thymidine (3H- TdR) incorporation assay 
Cells (2 x 104) were cultured for 72 hours in 96-well round-bottommicrot-
iter plates in 100 pI SFM containing DT-GM-CSF (100 ng/ml). The effects 
of DT-GM-CSF were tested in the absence of growth factors, and in the pre-
sence of the combination of human stem cell factor (SCF 0.1 pg/ml; a gift 
from Amgen Biologicals, Thousand Oaks, CA, USA), human interleukin-3 
(IL-3 0.025 pg/ml; a gift from Gist Brocades, Delft, The Netherlands) and 
human granulocyte-colony stimulating factor (G-CSF 0.1 pg/ml; Amgen). 
Eighteen hours before harvesting, 0.1 pCi 3H-TdR (2 Ci/mmol, Amersham 
International, Amersham, UK) was added to each well. Cells were collected 
using an automatic cell harvester (Skatron, Lier, Norway), and the ceil-asso-
ciated radioactivity was measured in a liquid scintillation counter 
(Pharmacia-LKB, Bromma, Sweden). In competition experiments an excess 
of GM-CSF (2 pg/ml) was added simultaneously with DT-GM-CSF. All cul-
tures were performed in triplicate. Data are expressed as percentage of con-
trol. 
SCID mice and transplantation of AML 
Female specific pathogen-free CB17 SCID/SCm mice (5-8 weeks of age) 
were obtained from Harlan CPB, Austerlitz, The Netherlands, and housed 
under pathogen free conditions in a laminar air flow unit. The mice were 
supplied with sterile food and acidified drinking water with 100 mg/L 
ciprofloxacine (Bayer AG, Leverkusen, Germany). The mouse plasma Ig 
level was determined with an ELISA using a sheep anti-mouse antibody 
reacting with mouse IgG and IgM (Boehringer Mannheim Biochemica, 
Penzberg, Germany). Mice with plasma Ig levels over 40 pg/ml were exclu-
ded. scm mice were pretreated with 0.2 ml dichloromethylene diphospho-
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nate (CL2MDP) liposome stock solution, injected into the lateral tail vein, 
on the day before transplantation of the leukemic cells to eliminate the 
macrophages in spleen and liver (28). In addition, total body irradiation at 
a dose of 3.5 Gy was delivered by a I37Cs source (Gamma cell, Atomic 
Energy of Canada, Ottawa, Canada) adapted for the irradiation of mice. 
The AML graft size was the equivalent of 30 x 10' AML input cells for all 
three samples. The grafts, suspended in 300 pi Hanks balanced salt solution 
(HBSS) (GIBCO, Breda, The Netherlands), and 0.1 % bovine serum albu-
men (BSA, Sigma, St Louis, MO, USA), were injected into the lateral tail 
vem. 
Tissue collections 
The experiments were carried out following consent of the Institutional 
Ethics Committee for animal experiments. SCID mice were sacrificed using 
C02 inhalation followed by cervical dislocation in accordance with institu-
tional animal research regulations. Cell suspensions were prepared from the 
BM and analysed by flow cytometry. 
Flotu cytometric analysis of SCID mouse derived AML cells 
To quantify AML growth and to compare the immunophenotype with the 
initial graft samples, cells recovered from the bone marrow of SCID mice 
were incubated with the following (combinations of) mouse monoclonal 
antibodies: CD34-FITC, CD34-PE, CD38-PE, CD34-FITC/IgGI-PE, 
CD34-FITC/HLA-DR-PE, CD34-FITCICD38-PE, CD34-FITCIC-Kit-PE, 
CD34-FITCICD33-PE, CD45-FITCICD33-PE. All antibodies were obtained 
from Becton Dickinson, San Jose, CA, with the exception of c-kit-PE 
(Immunotech, Marseille, France). Cells recovered from SCID mouse bone 
marrow staining with two antibodies specific for human hemopoietic cells 
were counted as human cells (29). Mouse IgGl-FITC and mouse IgGI-PE 
conjugated antibodies and samples from non-transplanted SCID mice were 
used as controls. Samples were analysed using the FACScan flow cytometer 
and Lysis II software (Becton Dickinson, Mountain View, CAl. Erythrocytes 
and dead cells were excluded by gating on forward and orthogonal light 
scatter. 
Serum free colony assay for leukemic progenitors 
Cells were plated in 35-mm dishes (Becton Dickinson) in 1 ml Dulbecco's 
modified Eagle's medium (DMEM, GIBCO, Gaithersburg, MD) containing 
0.9% methylcellulose, 1.5% BSA (Sigma), insulin (10 pg/ml, Sigma), linol-
eic acid (1.5xl0-5moVI, Merck, Darmstadt, Germany), cholesterol (1.5xl0· 
'molll, Merck), sodium selenite (lxl0-7moVI, Merck), ~-mercaptoethanol 
(lxl0·'moVI, Merck), human transferrin (0.62 mg/ml, Behring Werke, 
Marburg, Germany), penicillin (100 U/ml, GIBCO), and streptomycin (850 
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pg/ml, GIBCO). Assays were performed in triplicate in the presence of GM-
CSF (5 ng/ml), IL-3 (10 ng/ml), and G-CSF (100 ng/ml). Colonies were sco-
red after 14 days of incubation at 3TC in humidified 5% C02 atmosphere. 
Colony assay for normal hemopoietic progenitors 
Colony-forming unit-granulocyte macrophage (CFU-GM) and burst-for-
ming unit-erythroid (BFU-E) were enumerated to test toxicity of DT-GM-
CSF to normal committed progenitor cells. DT-GM-CSF exposed nBM cells 
were plated at lx104 cells per dish in 1 ml of semisolid medium, (1.2% 
methylcellulose in Iscove's modified Dulbecco's medium (IMDM); GIBCO) 
containing 30% fetal calf serum (Hyclone, Logan, UT, USA) supplemented 
with 0.75% BSA (Sigma), penicillin (100 U/m!), streptomycin (100 pg/ml), 
~-mercaptoethanol (5xl0·5 M), erythropoietin (Epo 1 U/ml; Boehringel; 
Mannheim, Germany), IL-3 (15 ng/ml), G-CSF (50 ng/ml), GM-CSF (5 
ng/ml) and murine SCF (100 ng/ml; Genetics Institute, Cambridge, MA) all 
at final concentrations. Cultures were kept at 3TC and 5% C02 in a hum-
idified atmosphere. CFU-GM and BFU-E colonies were counted on day 14 
of cultlll'e in the same dish. 
CAFC Assay 
The CAFC assay was performed as described (24,25), using similar condi-
tions for normal and leukemic samples. Briefly, confluent stromal layers of 
FMBD-1 cells in 96-wells plates were overlaid with AML cells or normal 
bone marrow cells in a limiting dilution setup. The cells were cultured in 
IMDM (GIBCO) supplemented with 20% horse serum (GIBCO) and 
hydrocortisone 21-hemisuccinate (10 6M, Sigma). IL-3 (12.5 ng/ml) and G-
CSF (20 ng/ml) were added weekly to the cultures. Input values were the 
equivalent of 50,000 nucleated cells (NC) per well in the lowest dilution. 
Twelve dilutions two-fold apart were used for each sample, with 15 repli-
cate wells per dilution. The percentage of wells with at least one phase-dark 
hemopoietic clone of at least five cells beneath the stromal layer was deter-
mined about every 14 days and CAFC frequencies were calculated using 
Poisson statistics as described (30). 
RESULTS 
Alltiproliferative effects of DT-GM-CSF in a proliferation assay 
The response of AML samples to GM-CSF or a mix of cytokines (G-CSF, 
IL-3 and SCF) was determined in a proliferation assay (Table 1). AML cells 
from patients A and B proliferated when exposed to GM -CSF, indicating the 
presence of functional GM-CSFR. AML cells from patient C showed no 
proliferative response to GM-CSF. All samples proliferated when incubated 
Fig 1 
Proliferation inhibition of cells from AML A, Band C by varying concen-
trations of DT-GM-CSF as measured in the JH_ TdR incorporation assay. 
AML cells were incubated in cytokine-free medium (D) and in SCF, IL-3 
and G-CSF (0 )containing medium. The effect of DT-GM-CSF was also 
tested in the presence of an excessof GM-CSF (2 flg/ml) simultaneollsly 
with DT-GM-CSF in cytokine free medium (III) or SCF, IL-3 and G-CSF 
containing medium (e). Values are given as percentages of controls 
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with the combination of G-CSF , 1L-3 and SCE 
To determine the effect of DT-GM-CSF on unstimulated proliferation we 
incubated the AML cells for 72 hours at DT-GM-CSF concentrations ran-
ging from 0.001 to 500 ng/ml without growth factors. Similar experiments 
were performed in the presence of the combination of G-CSF, 1L-3 and SCF 
(Fig 1). Table 1 shows the ID50, i.e. the DT-GM-CSF dose required to indu-
ce a 50% inhibition of DNA synthesis of the AML cells. The AML cells 
from patients A and B were sensitive to the toxin under both conditions and 
the toxic effect could be inhibited by an excess amount of GM -CSE The 
1D50 varied from 0.04 to 5 nglml. AML cells from patient C were insensi-
tive to DT-GM-CSF; even a concentration of 500 ng/ml failed to induce an 
antiproliferative effect. These results correlated with AML cell viability after 
incubation with DT-GM-CSF for 48 hours as assessed by trypan blue stai-
niug: the numbers of viable cells were reduced to 18% for patient A and 3% 
for patient B as compared to the control incubations. The viability of AML 
cells from patient C was unchanged at 97%. 
Restimulation of the AML cells of patients A and B recovered after incuba-
tion with DT-GM-CSF revealed that the cells surviving DT-GM-CSF expos-
ure were unable to proliferate in response to GM-CSF or the combination 
of G-CSF, 1L-3 and SCE The proliferation pattern of AML cells from patient 
C was unchanged: no response to GM-CSF and proliferation in response to 
the combination of growth factors (data not shown). Culturing of the cells 
in a cionogenic assay revealed that after DT-GM-CSF incubation CFU-AML 
numbers were reduced to 2.2% (pat A) and 0.7% (pat B) as compared to 
controls. AML cells from patient C did not produce colonies at all. 
I Table I Effect of DT-GM-CSF on AML cells in the 3H-TdR uptake assay I 
AML FAB JH-TdR uptake (cpm x 103) ID 50 (nglml) 
ngf" GM-CSF SCFIIL-3 autonomous stimulated' 
IG-CSF growth growth 
A M2 1.3 8.2 33.5 0.1 5 
B M1 1.2 9.8 35.5 0.04 0.7 
C M1 1.6 2.0 31.4 >500 >500 
Cells fram 3 AML patiel1ts diagl10sed accordil1g to the criteria of the Frel1ch-
American-British committee were incubated ill serum-free medium with or without a 
mixtllre of SCR IL-3 al1d G-CSR The ID50 is the COl1cel1tratiol1 of DT-GM-CSF 
reqllired for 50% il1hibitiol1 of the alltol1omOIlS proliferatiol1 or the proliferatiol1 
1111der stimlliatory cOl1ditiol1s. ,. 110 growth factor' 111 the presel1ce of SCF, IL-3 al1d G-
CSF 
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The concentration of 100 ng/ml of DT-GM-CSF was selected as an effecti-
ve dose in later experiments, because maximal efficacy in the proliferation 
assay was already achieved at considerably lower concentrations. Exposure 
for longer periods of time (up to 72 hours) did not result in a change in the 
viability of the exposed AML samples (data not shown). 
Outgrowth of DT-GM-CSF exposed, GM-CSF exposed and control AML 
cells in SCID mice 
The effect of the described interventions on in vivo leukemia initiating capa-
city of the AML cells was investigated using transplantations into scm 
mice. Groups of 5 SCID mice were evaluated 30-48 days after transplanta-
tion. The mice that had received a DT-GM-CSF treated graft of AML A and 
B, showed a much lower percentage of leukemic cells as compared to con-
trol mice (Table 2). In mice transplanted with DT-GM-CSF exposed cells 
from AML B, all grafts failed (graft failure was defined as less than 0.5% of 
AML cells proliferating in the SCID mouse bone marrow). DT-GM-CSF tre-
atment of AML cells from patient C did not lead to a significant reduction 
in leukemic cell load in the mice. The results also show that exposure of 
AML cells to GM-CSF (48 hours, SFM) did not result in an appreciable 
increase of the leukemic cell load in scm mice (Table 2). 
Table II Outgrowth of DT-GM-CSF exposed, GM-CSF exposed and 
control AML cell tJopulations in SCID mice. 
AML Incubation % human cells 
in SCID mouse BM 
A control 75 ± 13 
GM-CSF 64 ± 11 
DT-GM-CSF 12 ± 8.7 
B control 21 ± 9.2 
GM-CSF 31 ± 21 
DT-GM-CSF 0 
C control 42 ± 9 
GM-CSF 50 ± 19 
DT-GM-CSF 21 ± 7 
# Meall IIlIlItber of percelltage of /lUmall cells ill SCID mOllse bOlle marrow 
± Stalldard deviation. Vailies calclilated 011 the basis of data from five groups of trans-
plallted mice. 
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F1oU! cytometric analysis of AML cells from the SCID mouse bone marroU! 
Cells recovered from the SCID mouse bone marrow were investigated for 
leukemic origin. Flow cytometry with the described panel of monoclonal 
antibodies showed that the phenotypes of the AML cells recovered from the 
SCID mice were identical to the grafts, except in AML case A (data not 
I Fig 2 
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shown). In case A the phenotype converted from 75% CD34 negative AML 
cells to a phenotype entirely negative for CD34 expression. Additional sup-
port for the leukemic nature of the cells proliferating in the SCID mice 
comes from the observation that nBM does not proliferate extensively in 
SCID mice under the experimental conditions used (unpublished observa-
tion). 
Proliferation assay of AML cells recovered from the SCID mouse bone marrow 
Cells recovered from SCID mice that had received a DT-GM-CSF exposed 
graft from patient A proliferated in response to GM-CSF. Renewed incuba-
tion with DT-GM-CSF reduced proliferation (data not shown). Because 
such AML cells could not be demonstrated in the initial graft, directly after 
the incubation, these data indicates that GM-CSF and DT-GM-CSF respon-
sive cells regenerated in the mouse. 
Outgrowth of DT-GM-CSF exposed AML cells in the CAFC assay 
Long term growth of the DT-GM-CSF exposed AML cells from patient A, 
Band C was investigated in a quantitative long-term bone marrow culture 
system, the L-CAFC assay. It was shown that the frequencies of week 7 L-
CAFC were 6060 ± 1318 and 3828 ± 834 per 10' NC (mean ±SEM) in case 
A and B respectively (Fig 2), whereas this frequency in unfractionated nBM 
always varies between 0.1 and 10 per 10' NC. Therefore the origin of the 
great majority of the cobblestone areas produced by case A and B must be 
leukemic. The frequency analysis of leukemic progenitors after 7 weeks of 
culture (late L-CAFCs) showed a 7 and 87 fold reduction in the DT-GM-
CSF treated cell populations as compared to the control cells from patient 
A and B, respectively. The L-CAFC assay of the DT-GM-CSF exposed cell 
sample of patient C showed that week 7 L-CAFC frequencies were 3.2 ± 
0.6/10' as compared to 4.0 ± 0.7/10' for control cells from patient C, and 
Table 3 Relative effect of DT-GM-CSF exposure on normaal 
hemopoietic progenitor cells 
CFU-GM BFU-E CAFC CAFC 
# # week 2 week 6 
## ## 
mean 90.2 ± 19.2 147.6 ± 32.5 119.2 ± 32.9 113.1 ± 14.8 
range 73 - 127 100 - 190 76 - 157 88 - 126 
# values calculated as the percentage of controls (±SD) from CAFC assays of normal 
bone marrow samples 
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was therefore unchanged. The L-CAFC data indicates that the great majo-
rity of leukemic stem cells of patient A and B were sensitive to DT-GM -CSF, 
which is in agreement with the in vivo leukemia initiating capacity of these 
samples. 
Coincttbation of DT-GM-CSF with excess concentrations of GM-CSF 
To test whether the toxicity of DT-GM-CSF is conferred by the GM-CSFR. 
We incubated AML cells of patient A with DT-GM-CSF in the presence of 
an excess amount of GM-CSF and compared the result of incubation with 
the effect of excess GM-CSF alone. The frequency of week 5 L-CAFC (1254 
± 295110' and 1027 ± 41110' (mean ± SEM)) and the engraftment in scm 
mice (in groups of 5 mice 69 ± 14% and 64 ± 11 % (mean ± SD)) of AML 
cells in the SCID mouse BM, respectively) were similar, showing that the 
toxicity of DT-GM-CSF could be blocked by coincubation with an excess of 
GM -CSF. This implies that the toxicity to the AML stem cells is mediated 
via the GM-CSFR. We showed earlier that the effect of DT-GM-CSF on 
AML cells as determined in 3H-TdR incorporation assay could be preven-
ted by high concentrations of GM-CSF as well (17). 
Effect of DT-GM-CSF 011 normal hemopoietic tJl'ogenitors 
To investigate the cytotoxic effect of DT-GM-CSF to normal hemopoietic 
progenitor cells, five samples of nBM cells were exposed to 100 ng/ml DT-
GM -CSF for 48 hours in liquid culture. The relative effect on committed 
progenitors were determined in clonogenic assays by enumerating the num-
ber of CFU-GM and BFU-E's, and compare this with non-exposed nBM 
cells. Hemopoietic stem cell subsets were evaluated in the CAFC assay 
(Table 3) in which the week 2 CAFC correlates with the number of short-
term repopulating progenitor cells (25, 30) and week 6 CAFC correlates 
with long term repopulating stem cells. All frequencies of nBM progenitor-
subsets were unchanged after the in vitro DT-GM-CSF exposure. These 
data indicate that all hemopoietic progenitor cells, including the most pri-
mitive ones (week 6 CAFC), escape DT-GM-CSF induced cell kill. 
DISCUSSION 
Transplantation of AML cells into SCID mice may be used to determine in 
vivo growth of primitive AML cells (19, 21, 24,31). In this model we eva-
luated the sensitivity of human AML progenitor cells to in vitro treatment 
with DT fused to human GM-CSF. In 2 out of 3 AML samples, the long 
term repopulating AML cells, defined as the leukemia initiating cells in 
SCID mice, were reduced in number by DT-GM-CSF. In one of the cases 
(case B) AML growth in SCID mice was completely prevented by DT-GM-
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CSF. Although the reduction of MIL cell proliferation in case A and B was 
obvious, exact quantification of SCID mouse transplantation results requi-
res limiting dilution experiments (18). In the L-CAFC assay the DT-GM-
CSF induced a reduction in the number of AML cells with long-term abili-
ties (CAFC week 6-7), 8 fold and 87 fold in case A and B, respectively. 
An excess of unlabeled GM-CSF blocked the toxic action of DT-GM-CSF, 
indicating that leukemic stem cell reduction was mediated by the specific 
binding of DT-GM-CSF to the GM-CSFR, which is consistent with the spe-
cificity observed in experiments with murine GM-CSF fused to DT (12) and 
GM-CSF coupled to saporine (32). 
The applicability of growth factor toxins in vivo could be limited by side-
effects to non-leukemic cells bearing the same receptol; e.g. cells from the 
normal hemopoietic system that express GM-CSFR. However, exposure of 
normal bone marrow to a high dose of DT-GM-CSF for 48 hours did not 
result in a reduction of the numbers of erythroid (BFU-E), myeloid (CFU-
GM) and CAFC week 2 progenitor cells. Moreovel; primitive hemopoietic 
progenitors (CAFC week 6) remained unaffected by high concentrations of 
DT-GM-CSF. Based on the lack of toxicity induced by the DT-GM-CSF to 
these cells we conclude that primitive normal hemopoietic progenitor cells 
do not express functional GM-CSFR, which is consistent with data obtai-
ned by others (22, 23, 32). In addition to leukemic and normal hemopoie-
tic cells, non-hemopoietic tissues might be affected by DT-GM-CSF. 
High affinity complexes of the GM -CSFR have been identified on normal 
endothelial cells (33). Because GM-CSFR are also expressed on tumor cells 
e.g. colon adenocarcinoma cells, small cell lung carcinoma cells, osteogenic 
sarcoma cells and breast carcinoma cells (34-36), this might suggest that 
GM-CSFR is expressed on their normal counter parts. Therefore, it will be 
essential to evaluate the toxic side-effects of DT-GM-CSF in preclinical ani-
mal models, as we described earlier (37). 
DT-GM -CSF could be clinically useful; it may induce sufficient cell kill 
when applied in vivo, while in vitro autologous bone marrow grafts might 
be treated. DT-GM-CSF induces AML cell kill via an alternative mechanism 
than cytostatic drugs. This provides the means to eliminate leukemic cells 
that are resistant to cytostatic drugs. Experiments with 5-FU (24) showed 
that AML stern cells are resistant to the antimetabolite 5-FU, whereas in the 
same system a substantial reduction of week 6 CAFC and SCID mouse leu-
kemia initiating cells was observed as a consequence of exposure to DT-
GM-CSF. The optimal conditions for the use of DT-GM-CSF and its maxi-
mal efficacy have yet to be determined. 
In conclusion, these results show that DT-GM-CSF may be utilised to eli-
minate AML cells with the ability to initiate AML in vivo. The lack of toxi-
city to normal primitive progenitor cells suggests an exploitable therapeutic 
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window. These preclinical studies warrant further investigations of DT-GM-
CSF as a potential therapeutic agent in the treatment of AML. 
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GENERAL DISCUSSION AND SUMMARY 
AML stem cells may be defined as the subset of leukemic cells that express 
abilities to initiate and maintain long-term growth of AML. Until recently, 
human AML growth has mainly been studied in culture for limited periods 
of time (e.g. 1-2 weeks). Transplantation of human AML cells in various 
strains of mice resulted in transient and local growth. Thus, the available in 
vitro and in vivo systems, did not allow for study of long-term growth of 
AML cells. More recently, transplantation of primary human AML cells 
into newly developed strains of immunodeficient mice (severe combined 
immunodeficient (SCID) and non obese diabetic (NOD)/SCID mice has 
resulted in reproducible growth of AML for prolonged periods of time (see 
Introduction). Furthermore long-term bone marrow culture systems (e.g. 
the cobblestone area-forming cell assay) have become available to sustain 
normal and malignant hematopoiesis over periods of 2 to 4 months. These 
models of growth of human leukemias have provided assays for investiga-
ting long-term growth of AML and furnished insight into the characteristics 
of more primitive AML stem cells. 
Frequency of AML stem cells 
The leukemic stem cell is a rare cell. Limiting dilution experiments of AML 
in immunodeficient mice have shown that the frequency of the cells with the 
ability to initiate AML in immunodeficient mice ranges between 2 and 
1,000 per 10' AML cells. (1,2) The frequencies of cells with the ability to 
produce leukemic cobblestone areas (CA) after an interval of 5-8 weeks in 
long term bone marrow culture vary between 4 and 2,400 per 10' AML 
cells (Chapters 4, 5 and 6). These so called late cobblestone area-forming 
cells are assumed to represent primitive progenitors. Thus, the frequencies 
of cells initiating long-term growth of leukemia in vivo and cobblestone 
areas in culture beyond 4 weeks are similar. This suggests that they proba-
bly represent identical or closely related cell populations. Nevertheless, 
these quantitative estimations are only approximations. Due to residual 
graft resistance of the mouse recipients and seeding efficiency of hemato-
poietic cells in culture these values may be underestimations. The variations 
observed in the frequencies of the AML stem cells among individual cases 
are most likely exponents of the heterogeneity of clinical AML. 
Are these cells capable of maintaining AML growth indefinitely? This 
question remains unresolved. In one case leukemic growth could be main-
tained in SClD mice for as long as 100 days (Chapter 4). Leukemia could 
be reinitiated after transplantation of AML into secondary mouse reci-
100 
pients. Human AML cells recovered from the recipient bone marrow con-
tained AML progenitor cells (colony forming unit-AML (CFU-AML)) and 
these progenitor cells could also be maintained in the mouse for a minimum 
of 100 days. (Chapter 4 and references 1, 2, 3). Thus, the data show that 
human AML cells with proliferative abilities may survive without exhaus-
tion in the murine bone marrow environment for extended periods of time. 
Additional experiments would be needed to define any time restriction of 
AML growth in these animals. 
Immunophenotype of AML stem cells 
Normal primitive hematopoietic cells may be enriched according to immu-
nophenotype as they express CD34 brightly, but do not show CD38 or line-
age-associated antigens. These CD34H /CD38- cells are present at a frequen-
cy of 0.01 % in normal bone marrow. (4) Flow-cytometric analysis of more 
than 90 AML samples disclosed that CD34 positive cells can be identified 
among the leukemic cell population in 83% of cases. CD34H /CD38- AML 
cells are demonstrable in 35% of cases. This phenotypically distinct subset 
of cells is present at variable frequencies. (5) These data suggest that primi-
tive AML cells might express the normal CD34 H /CD38- phenotype in many 
instances. 
The characteristics of subsets of cells can be conveniently examined follo-
wing cell separation, e.g. using immunomagnetic beads or fluorescence acti-
vated cell sorting. In chapter 4 data are presented of a case of AML that 
contains a CD34"CD38-fraction. The leukemic cells were separated into 
CD34 positive and CD34 negative fractions. AML growth could be initia-
ted either by the CD34 positive or CD34 negative AML cell subsets. 
Following transplantations into SCID mouse recipients, both cell fractions 
infiltrated the mouse bone marrow to a similar degree. The leukemia deri-
ved from the CD34 negative AML cells could be maintained for at least 100 
days. Leukemic cells recovered from mice that had received CD34 negative 
grafts contained AML progenitor cells (CFU-AML). Further, leukemic cells 
recovered from these primary mouse recipients initiated leukemia in secon-
dary recipients. Finally, in vitro investigations showed that the CD34 nega-
tive fraction contained considerable numbers of cells with the ability to pro-
duce Cobblestone Areas (CA) after 8 weeks of culture. Taken togethel; the 
data indicate that the CD34 negative fraction of the leukemia expressed the 
abilities to initiate and maintain AML growth in vivo (>100 days) and in 
vitro (>8 weeks). The CD34 positive fraction of this leukemia had similar 
leukemia initiating abilities. Thus, in this case the primitive AML progeni-
tors were inhomogeneous and expressed a diverse CD34 positive or a CD34 
negative immunophenotype, which is in contrast to normal hematopoiesis. 
How do these data compare to the results previously reported by other 
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investigators? The phenotype of AML cells with the ability to engraft immu-
nodeficient mice were always CD34'/CD38- in another study. (1) In a third 
study analysis of the abilities of subsets defined by expression of CD34 and 
Thy-1 showed that the phenotype of AML cells with long-term abilities 
was CD34+/Thy1- in 5 of 6 cases evaluated.(6) In one case CD34' cells fail-
ed to initiate leukemia and only CD34-cells showed the ability to engraft. 
Thus, the CD34'/CD38- subset of AML generally contains AML cells with 
long term potential. However, such AML cells occur in a minority of cases. 
(5) AML stem cells may express variable immunophenotypes. Apparently, 
expression of the CD34 antigen is not strictly associated with long-term abi-
lities of AML. 
AML progenitors more immature than CFU-AML 
The AML progenitor cell identified as CFU-AML actively synthesizes DNA. 
This has been shown in thymidine suicide studies.(7) In normal bone mar-
row, the antimetabolite 5-fluorouracil (5-FU) preferentially eliminates 
hematopoietic cells that are in S-phase or have active mRNA synthesis. (8) 
5-FU resistance is a property of murine hematopoietic cells with long-term 
in vivo repopulating abilities (LTRA) and long-term abilities in vitro, indi-
cating that these cells are mainly in a kinetically quiescent state (GO-phase). 
(9-13) Most early human hematopoietic progenitors show similar resistan-
ce to 5-FU.(14,15,16) Prolonged incubation of unseparated human hema-
topoietic cells with 5-FU in the presence of cytokines selects for pluripotent 
cells in GO phase with an immature phenotype.(17) Incubation with 5-FU 
may be used as a strategy to select for stem cells. 
Chapter 5 summarizes experiments designed with the purpose to investiga-
te whether the AML cell population contains AML cells more immature 
than the AML-CFU. Exposure of AML cells to 5-FU in vitro eliminated up 
to 3 log of the AML-CFU subset. However most AML cells initiating leu-
kemia in SCID mice survived the 5-FU treatment. Similarly, a major fraction 
of primitive leukemic CAFC (i.e. 31-82% as assessed at week 6 in culture) 
retained their viability after exposure to 5-FU. Thus, apparently, the AML 
cell population contains a 5-FU resistant fraction of cells with long-term 
abilities in vivo and in vitro, a condition similar to normal hematopoiesis. 
Because growth of AML may be initiated with AML cell populations deple-
ted of AML-CFU, AML-CFU are not representative of leukemic stem cells. 
As the week 2 CAFC have a sensitivity to 5-FU that is greater than that of 
week 6 CAFC and less than that of AML-CFU (Chapter 5), the maturation 
stage of week 2 CAFC apppears intermediate between CFU-AML and week 
6 primitive CAFe. 
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Hierarchy of the AML cell population 
The data discussed above show that AML cells constitute a hierarchically 
ordered cell population. This hierarchy resembles that of normal hemato-
poiesis in many but not all respects. ScrD mouse leukemia initiating cells 
and week 6 CAFC measure closely related AML cell populations. Immature 
precursors in AML may be CD34 negative, which is in contrast to normal 
hematopoiesis. This appears indicative of a maturation asynchrony in cer-
tain cases of leukemia. The question at which maturation stage more exact-
ly the AML cell loses its long-term potential requires more detailed study. 
I Figure 1. AML cell maturation model. 
Leukemic 
stem cells 
week 6 
CAFC 
SCID mouse 
leukemia 
iniliating cells 
Immature leukemic cells 
long term capacity 
5-FU resistant 
CD34 positive or negative 
week 2 
CAFC 
• 
CFU-AML non-clonogenic AML cells 
more mature leukemic cells 
non-cionogenic AML cells 
5-FU sensitive 
The sizes of the populations and the overlaps are arbitrary 
Possible application of assays for primitive AML progenitors to the 
development of AML therapy. 
Several investigators have correlated the in vitro sensitivity of CFU-AML to 
cytostatic drugs with the clinical efficacy of these drugs. Howevel; to date 
these tests have unsatisfactory predictive value.(18) The deleterious effects 
of individual cytostatic drugs on transient and long-term growth of normal 
bone marrow could be predicted using results of the CAFe assay.(19, 20) In 
chapter 5 experiments in AML with 5-FU showed minimal cell kill of pri-
mitive AML cell progenitors and considerable killing of more mature AML 
cell subsets. Thus, the quantification of cytotoxic effects specifically targe-
ted at primitive versus less primitive subsets of AML is feasible. Primitive 
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AML cells as an index of the repopulative potential of the neoplasm, may 
be the target of choice for the development of AML therapy. 
A potential novel therapeutic agent was evaluated in chapter 6. Diphtheria 
toxin was coupled to the hematopoietic growth factor GM-CSF. The resul-
ting fusion toxin (DT-GM-CSF) was incubated with AML cell samples and 
normal bone marrow. Leukemic stem cells as measured in SCrD mice and in 
the CAFC assay were reduced by DT-GM-CSF (in 2 of the 3 cases investi-
gated). Probably, leukemic stem cells specifically bind DT-GM-CSF via the 
GM-CSF receptor. Normal stem cells howevel; survived the incubation. The 
fact that application of DT-GM-CSF resulted in selective AML cell kill, sup-
ports the possibility of the clinical application of this agent. The observation 
that primitive leukemic stem cells express receptors for GM -CSF in itself 
may hold interesting possibilities for the use of hematopoietic growth fac-
tors for modulation of AML growth. The assessment of antileukemic effects 
specifically directed at the more primitive leukemic stem cells may hold a 
broader promise for the preclinical evaluation and comparison of antileu-
kemic therapies. The ScrD mouse and CAFC assays for immature AML 
precursors may thus be used in treatment development and perhaps as pre-
dictive assays for therapeutic effects of cytotoxic agents. 
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SAMENVATTING 
Acute myeloide leukemie (AML) is een kwaadaardige ziekte van de bloed-
vormende cellen in het beenmerg. Zij tonen een onvermogen om uit te rij-
pen tot norma Ie bloedcellen. AML cellen vallen op het eerste gezicht op 
door hun uiterlijke uniformiteit. Desondanks is het al geruime tijd bekend 
dat slechts een klein deel van aile AML cellen het vermogen bezit om nieu-
we leukemische cellen aan te maken. De meeste leukemiecellen zijn niet in 
staat om de ziekte in stand te houden. Tot voor kort werden leukemische 
voorlopercellen meestal in koloniekweken onderzocht. In dit celkweek sys-
teem ontstaan na ±2 weken kolonies van leukemische cellen. Elke kolonie 
stamt af van een enkele voorlopercel: de colony forming unit AML (AML-
CFU). Bij analyse van de eigenschappen van voorlopercellen van normaal 
beenmerg is gebleken dat dergelijke kolonie-vormende cellen niet represen-
tatief zijn voor stamcellen, de beenmergcellen die het vermogen hebben om 
de bloedcellen langdurig in stand te houden. 
In het hier beschreven onderzoek zijn twee nieuwe methoden gebruikt om 
de groei van AML gedurende een veellangere periode aan te houden: trans-
plantatie van humane AML cell en in muizen met een severe combined 
immunodeficiency (SCID-muizen) en AML celkweek in zogenaamde lange 
termijn beenmergkweken (de cobblestonearea-forming cell (CAFC) assay). 
SCID muizen hebben een aangeboren afwijking van het immuunsysteem, de 
T- en B-cel functies ontbreken. Daarom zijn zij ontvankelijk voor menselij-
ke transplantaten, zoals beenmerg. Het CAFC assay is een kweeksysteem 
met stromale cellen waarop menselijk beenmerg langere tijd in kweek 
gehouden kan worden. 
In hoofdstuk 1 wordt een korte inleiding gegeven over acute leukemie, 
hematopoietische stamcellen en de testen die in gebruik zijn voor het meten 
van de diverse voorlopercellen van normaal beenmerg. Dan voIgt een 
beschrijving van de tot dusverre bekende eigenschappen van de leukemische 
voorlopercel (AML-CFU), en de ervaring met SCID-muizen voor het evalu-
eren van normale en leukemische cellen. 
In de hoofdstukken 2 en 3 worden experimenten beschreven tel' definiering 
van optima Ie condities voor groei van humane AML in SCID-muizen. 
Onderzocht zijn de effecten van totale lichaamsbestraling van de muis, de 
grootte en toedieningsweg van het transplantaat en de bevordering van de 
uitgroei van de humane AML cellen met behulp van een hematopoietische 
groeifactor (interleukine-3) (hoofdstuk 2). In hoofdstuk 3 wordt de vraag 
gesteld of het blokkeren van de functie van maCl'ofagen van de ScrD muis 
de uitgroei van menselijke beenmergcellen zou kunnen vergemakkelijken. 
Macrofagen werden geelimineerd door toediening van met clodronaat bela-
den liposomen. Uit de resultaten bleek dat een gecombineerde voorbehan-
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deling van de SCID-muis met totale lichaamsbestraling en clodronaat lipo-
somen, gevolgd door de intraveneuze transplantatie van AML, de groei van 
AML in de muis bevordert. Ondersteuning met de groeifactor interleukine-
3 had ook een gunstig effect en was noodzakelijk in 3 van de 4 onderzoch-
te gevallen. 
In hoofdstuk 4 is de betekenis van expressie van de membraan merkel' 
CD34 op leukemische cellen onderzocht. Deze merkel' wordt aangetroffen 
op norma Ie beenmergcellen met het vermogen tot lange termijn groei. Het 
vermogen om lange termijn groei van leukemie te onderhouden van CD34 
positieve en van CD34 negatieve leukemiecellen werd vergeleken. Daartoe 
werden afzonderlijke fracties van CD34 positieve en CD34 negatieve cell en 
van Een leukemie in lange termijn beenmergkweek (CAFC assay) en SCID 
muizen onderzocht. De CD34 negatieve cellen bleken in muizen leukemie te 
veroorzaken en bij passage in een volgende genera tie muizen opnieuw leu-
kemie te initieren. Ook in het CAFC assay produceerden CD34 negatieve 
cellen grote aantallen leukemische klonen gedurende tenminste 8 weken. Dit 
betekent dat het ontbreken van expressie van CD34 niet altijd aangeeft dat 
een leukemische cel zijn primitieve stamcel eigenschappen verliest. 
In hoofdstuk 5 wordt de vraag gesteld of de cellen die uitgroeien in de SCID-
muis en in lange termijn beenmergkweek inderdaad vroegere leukemiecellen 
zijn dan de tot dan toe bekende voorlopercel AML-CFU. Hiertoe werden 
leukemische cellen blootgesteld aan zodanige concentraties van het cytosta-
ticum fluorouracil (5-FU), dat aile AML-CFU werden gedood. De overle-
vende cellen waren in staat om zowel in de SCID-muis als in lange termijn 
kweek groei van leukemie te initieren. Hieruit blijkt dat leukemische stam-
cellen niet identiek zijn aan AML-CFU. Het gegeven dat leukemische stam-
cellen dergelijke condities overleven is een aanwijzing dat ze geen actieve 
stofwisseling of actieve celdeling vertonen. 
Leukemiecellen hebben receptoren voor hematopoietische groeifactoren. 
Deze receptoren he ben een hoge affiniteit voor de corresponderende groei-
factor en een selectieve weefseldistributie. Het is mogelijk om toxinen aan 
groeifactoren te koppelen. Als een leukemiecel een dergelijk 
groeifactor/toxine bindt en internaliseert, wordt deze cel specifiek geeIimi-
neerd. In hoofdstuk 6 worden de effecten van een toxine bestaande uit de 
groeifactor GM -CSF en difterietoxine (DT-GM -CSF) op normale en leuke-
mische stamcellen onderzocht. Het blijkt dat norma Ie stamcellen een 48 uur 
durende expositie aan hoge concentraties van het toxine zonder schade 
doorstaan. Daarentegen leidt dezelfde blootstelling aan DT-GM-CSF wei 
tot verlies van leukemische stamcellen: zowel de lange termijn groei van leu-
kemie in SCID-muizen als die in het CAFC assay werd aanzienlijk vermin-
derd. De effecten van DT-GM-CSF bleken specifiek via de GM-CSF recep-
tor verlopen. Receptoren voor GM -CSF komen dus op de leukemische 
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stameel vaal', in tegenstelling tat de normale stanlCe!. Dit vel'sehil tussen 
leukemisehe en nal'male stameellen biedt patentieel thel'apeutisehe pel'spee-
tieven vaal' een gel'iehte benadel'ing van de leukemiepapulatie met antzien 
van de nal'male stamee!' 
Tenslatte wal'dt in haafdstuk 7 een averzieht gegeven van de huidige inzieh-
ten in de eigensehappen van de stameel van AML. Het is gebleken dat vaal' 
anderzoek van leukemisehe stameellen thans betere systemen besehikbaar 
zijn dan voorheen, In immunadeficiente muizen en in het CAFC assay kan 
een AML eelpapulatie ondel'zoeht worden die de 'eehte' leukemisehe stam-
eel betel' benadert. 
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ABBREVIATIONS 
:acute myeloid leukemia 
:all-trans retinoic acid 
:bone marrow 
:bovine serum albumin 
:cobblestone area 
:cluster of differentiation 
:cobblestone area-forming cell 
:colony forming unit 
:dichloromethylene diphosphonate 
:complete remission 
:colony stimulating factor 
:deletion 
:dimethylsulfoxide 
:deoxyribonucleic acid 
:decays per minute 
:diphteria toxin 
:diphtheria toxin fused to GM-CSF 
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:enzyme linked immunosorbent assay 
:French-American-British cytomorphological classification 
:fluorescence activated cell sorting 
:fetal calf serum 
:fluorescein isothiocyanate 
:fluorescent in situ hybridization 
:forward scatter 
:5-fluorouracil 
:granulocyte colony-stimulating factor 
:granulocyte-macrophage colony-stimulating factor 
:granulocyte-macrophage colony-stimulating factor receptor 
:Gray 
:human 
:Hank's balanced salt solution 
:hematopoietic growth factors 
:high proliferative potential 
:horse serum 
:immunoglobulin 
:interleukin-3 
:Iscove's modified Dulbecco's medium 
:intra peritoneally 
:intravenously 
:lymphokine activated killer 
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L-CAFC 
LTBMC 
LTC-IC 
LTRA 
a-MEM 
MGG 
MNC 
MoAb 
mRNA 
NA 
NC 
ND 
NK 
No 
NOD 
PB 
PBS 
PE 
PCR 
PIXY 
PML 
RAR 
R-G-CSF 
RNA 
SCF 
scm 
SD 
SEM 
SF 
SFM 
SSC 
TBI 
UCB 
:leukemic CAFC 
:long-term bone marrow culture 
:long-term culture initiating cell 
:long-term repopulating ability 
:alpha minimal essential medium 
:May-Griinwald-Giemsa 
:mononuclear cells 
:monoclonal antibody 
:messenger RNA 
:non-adherent 
:nucleated cells 
:not determined 
:natural killer 
:number 
:non-obese diabetic 
:peripheral blood 
:phosphate buffered saline 
:phycoerythrin 
: polymerase chain reaction 
:an IL-3/GM-CSF construct 
:promye!ocytic leukemia 
:retinoid acid receptor 
:G-CSF receptor 
:ribonucleic acid 
:stem cell factor 
:severe combined immunodeficiency 
:standard devia tion 
:standard error of the mean 
: serum-free 
:serum-free medium 
:sideward sca tter 
:total body irradiation 
:umbilical cord blood 
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